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The digestive enzyme carboxyl ester lipase (CEL) is mainly expressed in the acinar cells of the pancreas. 
We have previously identified disease-causing mutations in a variable number of tandem repeats 
(VNTR) domain, localised in the last exon of the CEL gene. Single base deletions (DEL1 or DEL4) in 
the VNTR lead to frameshifts and a truncated C-terminal of the CEL protein. Patients with these 
mutations suffer from exocrine pancreatic dysfunction and diabetes. In addition, a copy number variant 
of the CEL gene (CEL-HYB) with only 3 VNTR repeats has shown to be a novel risk factor for chronic 
pancreatitis.  
In this study, we wanted to further explore the role of the C-terminal domain of CEL in human pancreatic 
disease. We aimed to investigate the functional properties of not only previously characterized 
pathogenic variants, but also CEL variants identified in healthy controls. We also wanted to investigate 
whether a C-terminal epitope-tag could have an impact on our CEL protein studies.  
In HEK293 cells, we found that the expression and secretion of CEL variants varied with VNTR length 
and composition. Both pathogenic and normal CEL variants were observed in lysate and in insoluble 
fractions of the cell.  However, secretion of the disease-causing variants was reduced compared to 
secretion of the normal protein. When comparing CEL variants with and without tag, we observed a 
higher amount of untagged proteins intracellularly. Additionally, we found that several CEL variants 
induced apoptosis in HEK293 cells, but unexpectedly, some of these variants also led to increased cell 
viability. 
The CEL VNTR is known to be heavily O-glycosylated, which is thought to be important for proper 
folding, secretion and stability of the protein. Here, we obtained evidence that the three deletion variants 
(DEL1, DEL4 and DEL8), all with the same theoretical molecular mass (73 kDa) but different VNTR 
composition, are likely to contain different patterns of O-glycosylation. Furthermore, the variants 
differed in secretion with only the pathogenic proteins (DEL1, DEL4 and HYB) showing impaired 
secretion. We also confirmed that the pI increased from CEL-WT to CEL-DEL1 by isoelectric focusing 
(pI 5.1 and 9.5 respectively).  
In summary, we have shown that the cellular fate of CEL protein variants is influenced by the C-terminal 
of the protein. In addition, we found that epitope-tags most probably increase the solubility and stability 
of CEL proteins HEK293 cells, which may have led to an underestimation of the pathogenic effect of 





1.1. The pancreas 
The human pancreas is an organ located in the upper part of the abdominal cavity, behind the stomach 
(Fig. 1.1 A). The organ has an elongated structure, it normally weighs 85-100 g, and can be divided into 
a head, body and tail region (Putte et al., 2013). The head of the pancreas is surrounded by the duodenum 
(the first part of the small intestine) while the tail is located next to the spleen (Fig. 1.1 B). The two main 
blood vessels aorta and vena cava inferior are located behind the pancreas, providing the organ with a 
rich blood supply (Holck, 2015). The pancreas comprises mainly of glandular tissue, which serves both 
exocrine and endocrine functions.  
 
1.1.1. The exocrine pancreas  
The exocrine part of the pancreas constitutes approximately 95 % of the organ, and consists of acini and 
the ductal system (Fig. 1.1 B). The acini are built of clusters of acinar cells, which produce and secrete 
digestive enzymes into the small ductal tracts. The ductal cells produce and secrete bicarbonate and 
water, which together with the digestive enzymes form the pancreatic juice. The latter is transported to 
the duodenum via the ductal system, and serves important roles in digestion of food (Putte et al., 2013). 
The production of juice is regulated through the hormones secretin and pancreozymin from the small 
intestine, but also through nerve impulses. As much as one litre of pancreatic juice can be produced per 
day (Holck, 2015).  
The digestive enzymes are secreted as inactive forms (zymogens) to the intestine, to prevent self-
digestion of the pancreas (Putte et al., 2013). The three main types of enzymes are proteases, lipases and 
amylases (Table 1.1). The acidic content of the stomach is partly neutralized by the alkaline bicarbonate, 




Figure 1.1 Structure and histology of the human pancreas. A) The pancreas (yellow) is located behind the stomach, in the 
upper part of the abdominal cavity and is surrounded by other organs including the small intestine, spleen and liver. B) The 
exocrine pancreas secretes digestive enzymes to the small intestine via the pancreatic ducts, whereas the alpha and beta cells 
of the islets of Langerhans produce metabolic hormones that are secreted to the circulatory system. C) Histological section of 
the human pancreas. (The illustrations are adapted from Seeley`s anatomy and physiology (Putte et al., 2013)).  
 
1.1.2. The endocrine pancreas 
The endocrine part of the pancreas constitutes only 1-2 % of the total organ. It consists of specialized 
cells located in the islets of Langerhans, all of which produce and secrete their specific metabolic 
hormones to the circulatory system (Pocock et al., 2013). The pancreatic islets are embedded in the 
exocrine tissue (Fig. 1.1 B, C). There are 500,000 - 1 million islets, each made up of mainly alpha (20%) 
and beta cells (75%) (Holck, 2015). The alpha cells produce and secrete glucagon, while the beta cells 
produce and secrete insulin (Putte et al., 2013). Insulin and glucagon have opposite effects, and the 
production of these hormones is regulated by the glucose levels in the blood. A rise in blood-glucose 
triggers production of insulin, which increases glucose-uptake in the tissues. This, in turn, promotes 
storage of glucose as glycogen in the liver, and thus the glucose level in the blood is reduced. Glucagon 
production is activated upon low levels of blood-glucose, which promotes breakdown of the glycogen 
storages (Holck, 2015). 
The remaining endocrine tissue consists of delta-, gamma- and epsilon cells that produce somatostatin, 
pancreatic polypeptides and ghrelin, respectively (Table 1.1) (Putte et al., 2013).  
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Table 1.1 Overview of secreted endocrine and exocrine products from the pancreas.  
 
 
1.2. Diseases of the pancreas 
The most common diseases of the pancreas are diabetes mellitus, inflammation of the pancreas 
(pancreatitis) and pancreatic cancer (Holck, 2015). Whereas diabetes affects the endocrine part of the 
gland, the other diseases are primarily affecting the exocrine tissue. 
 
1.2.1. Diabetes mellitus 
Diabetes mellitus, commonly referred to as diabetes, is a group of metabolic diseases in which the body 
fails to regulate blood glucose levels properly, rendering them chronically elevated. Diabetes is 
considered to be the fifth leading cause of deaths worldwide (Leslie et al., 2013).  
Type 1 diabetes (T1D) represents between 5-10 % of all diabetes cases. T1D is an autoimmune disease, 
caused by the immune system attacking the beta cells (Leslie et al., 2013). This leads to reduced beta 
cell mass and reduced insulin production. As T1D is incurable, patients suffering from this disease 
require insulin replacements to regulate blood glucose levels (Leslie et al., 2013, Atkinson et al., 2014). 
The most common type of diabetes is Type 2 diabetes (T2D), which accounts for approximately 90% 
of all diabetes cases. T2D is considered to be a multifactorial disease caused by a combination of genetic 
Secretion Activated response
Exocrine product
Carboxypeptidase A Digestion of proteins
Carboxypeptidase B Digestion of proteins
Carboxyl ester lipase (CEL) Digestion of lipids
Chymotrypsin Digestion of proteins
Colipase Facilitates lipase function
Deoxyribonuclease Digestion of DNA
Elastase Digestion of proteins
HCO3
- Neutralization of acidic chyme
Pancreatic α-amylase Digestion of starch
Phospholipase A2 Digestion of lipids
Ribonuclease Digestion of RNA
Triacylglycerol lipase Digestion of lipids
Trypsin Digestion of proteins
Endocrine product
Ghrelin Regulates appetite 
Glucagon Increases blood glucose levels and stimulates secretion of insulin and 
somatostatin
Insulin Reduces blood glucose levels and inhibits glucagon secretion
Pancreatic polypeptide Inhibits pancreatic bicarbonate- and protein secretion
Somatostatin Inhibits secretion of insulin, glucagon and pancreatic polypeptides
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susceptibility and an unhealthy lifestyle. It is highly associated with obesity (Leslie et al., 2013), and the 
prevalence of T2D also increases with age. Furthermore, T2D is often linked to risk factors such as high 
blood pressure, high levels of fatty acids in the blood, thrombosis and abdominal obesity. T2D is caused 
by impaired insulin production as well as impaired insulin sensitivity, so that tissues do not fully respond 
to the insulin which is produced. A proper diet and physical activity are the two main actions against 
this disease. However, various drugs to lower the blood glucose content are also given to patients (Leslie 
et al., 2013, Kahn and Davidson, 2014). 
Other forms of diabetes include gestational diabetes and monogenic diabetes. Whereas T1D, T2D and 
gestational diabetes are complex diseases, monogenic diabetes is caused by mutations in one single gene 
(Murphy et al., 2008). Monogenic diabetes can be sub-divided into maturity onset diabetes of the young 
(MODY), neonatal diabetes and mitochondrial diabetes, where MODY is the most common form. 
Monogenic diabetes is a rare disease, accounting for approximately 2 % of all diabetes cases. There are 
more than 20 different genes that have been linked to this disease (Molven and Njolstad, 2011), however, 
patients suffering from monogenic diabetes are often misdiagnosed with T1D or T2D (Kavvoura and 
Owen, 2014). It has been reported that as many as 80% of MODY cases may be misclassified (Shields 
et al., 2010).  
 
1.2.2. Pancreatitis 
Pancreatitis is divided into an acute and a chronic form. Acute pancreatitis is characterized by fluid 
retention and swelling of the pancreas, caused by impaired drainage of pancreatic enzymes to the 
intestine. The disease mechanism is related to inappropriate activation of digestive enzymes in the 
pancreas, characterized by elevated levels of serum amylase and lipase. This can cause an inflammatory 
response leading to pancreatic tissue damage. The most common cause of acute pancreatitis is alcohol 
abuse and gallstones. Patients suffering from acute pancreatitis must receive medical care, and one way 
to treat them is to let the patients undergo fasting to prevent the pancreas from producing more pancreatic 
juice than what is needed (Whitcomb, 2006, Mounzer and Whitcomb, 2013, Aabakken, 2016).  
If acute pancreatitis is not reversed, or if it recurs, it can progress into chronic pancreatitis. This condition 
is characterized by fibrosis, atrophy and further impaired function of the pancreas. As a result, food 
digestion will become increasingly affected, resulting in weight loss and diarrhoea. The patients often 
suffer from chronic pain, which can be difficult to treat. Some patients also develop diabetes as a 
complication. To prevent relapse of acute pancreatitis and subsequent development of chronic 
pancreatitis, the cause of the inflammation must be treated if possible. All patients must avoid alcohol, 
and they can be given perioral pancreatic enzyme replacement treatment. In very severe cases, surgical 
treatment is an option.  
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Pancreatitis is a complex disease and in recent years, genetics has also shown to play an important role 
in the disease development. In patients where environmental or metabolic factors do not explain the 
disease, genetic factors are considered particularly important (Whitcomb, 2013, Aabakken, 2016). 
Variants of PRSS1 (cationic trypsinogen), CFTR (cystic fibrosis transmembrane conductance regulator), 
SPINK1 (serine protease), CTRC (chymotrypsinogen C), CPA1 (carboxypeptidase A1) and CLDN2-
MORC4 locus have been identified at risk factors (Whitcomb et al., 1996, Sharer et al., 1998, Witt et 
al., 2000, Le Marechal et al., 2006, Witt et al., 2006, Rosendahl et al., 2008, Whitcomb et al., 2012). 
 
1.2.3. Pancreatic cancer 
Pancreatic cancer can originate both from the endocrine and exocrine tissue of the organ. However, 
approximately 80 % of the tumours are adenocarcinomas, originating from the exocrine tissue. While 
the most common risk factor for pancreatic cancer is smoking, other risk factors are diabetes, chronic 
pancreatitis and genetics (Lowenfels et al., 1993, Bond-Smith et al., 2012). 
 
1.3. Carboxyl ester lipase 
Carboxyl ester lipase (CEL), also known as bile salt-stimulated lipase (BSSL) (Hernell and Olivecrona, 
1974) or bile salt-dependent lipase (BSDL) (Abouakil and Lombardo, 1989), is a digestive enzyme 
mainly expressed in acinar cells of the pancreas and in lactating mammary glands as (Lombardo, 2001). 
From the mammary glands, the enzyme is secreted as part of the breast milk (Blackberg et al., 1981, 
Blackberg et al., 1987) and plays an important role in the digestion of fat in new-borns (Hui and Howles, 
2002). Low levels of the enzyme has also been detected in fetal liver (Roudani et al., 1995), macrophages 
(Kodvawala et al., 2005), eosinophils (Holtsberg et al., 1995) and endothelial cells (Li and Hui, 1998, 
Lombardo, 2001).  
CEL is one of three lipases secreted from the exocrine part of the pancreas and comprise about 4% of 
the total proteins detected in the pancreatic juice (Lombardo et al., 1978, Lombardo et al., 1980b). The 
protein is secreted to the digestive tract as an inactive enzyme. Once activated by bile-salts in the 
duodenum, the enzyme has wide substrate specificity and hydrolyses substrates such as cholesteryl 
esters, triacylglycerids, phospholipids, and fat-soluble vitamins (Lombardo et al., 1980b, Lombardo et 
al., 1980a, Lombardo and Guy, 1980, Blackberg et al., 1981, Hui and Howles, 2002, Kolar et al., 2016). 
It has been reported that CEL can be transported from the duodenum to the blood by transcytosis in 
intestinal cells (Bruneau et al., 2003). In the blood, CEL can further associate with low density 
lipoproteins (Caillol et al., 1997). As CEL is cleared from the circulation by renal glomerulus filtration, 
it is detected in the urine of healthy individuals (Comte et al., 2006). 
11 
 
1.3.1. The CEL gene 
The human CEL gene is approximately 10 kb in size and consists of 11 exons. The gene is located on 
chromosome 9q34.3. The last exon of CEL includes a variable number of tandem repeats (VNTR) region 
(Fig. 1.2) (Taylor et al., 1991, Lidberg et al., 1992). These repeats consist of nearly identical 33 base 
pair segments, thus encoding 11 amino acids each. In the general population, the number of VNTR 
repeats varies from 3 to 23, and several studies have shown that the most common allele contains 16 
repeats. (Lindquist et al., 2002, Higuchi et al., 2002, Raeder et al., 2006, Torsvik et al., 2010, Ragvin et 
al., 2013). This corresponds to a protein of 745 amino acids. 
The human CEL locus also includes a nearby CEL pseudogene, a tandemly arranged gene designated 
CELP (Fig. 1.2). It has been proposed that CEL evolved from CELP through gene duplication, and that 
the original gene has lost its function (Lidmer et al., 1995, Madeyski et al., 1998, Lombardo, 2001, 
Vesterhus et al., 2010) Compared to CEL, CELP is missing exons 2-7 (Taylor et al., 1991, Lidberg et 
al., 1992). The remaining sequence however, shows 97 % similarity to CEL (Madeyski et al., 1998).  
 
 
Figure 1.2 Structure of the human CEL locus. The CEL gene (blue) and the CEL pseudogene CELP (yellow), located on 
chromosome 9q34.3. 
 
Furthermore, the CEL gene is highly conserved among vertebrates. However, while the gene is 
organized and positioned similarly with regard to introns and exons, it differs dramatically in the number 
of VNTR repeats. There are no repeats in fish, three in mouse, four in rat and as many as 39 in gorilla 
(Holmes and Cox, 2011). This is likely a result of internal duplications in the last exon during evolution, 
and indicates that the number of repeats is not critical for the function of the CEL enzyme (Kissel et al., 




1.3.2. CEL protein structure and secretion 
CEL belongs to the α/β hydrolase fold family of enzymes, composed of a beta-sheet core surrounded by 
alpha-helices. The protein is composed of two structural domains; an N-terminal globular core domain 
with both the catalytic site and a signalling peptide, and a C-terminal proline-rich VNTR region (Reue 
et al., 1991, Terzyan et al., 2000, Hui and Howles, 2002). The bile salt-binding sites are located in exons 
2, 3 and 10 (DiPersio et al., 1994, Aubert et al., 2002, Aubert-Jousset et al., 2004), as illustrated in Figure 
1.3. 
 
Figure 1.3 Schematic overview of the CEL protein. The protein is composed of two structural domains; the globular core 
domain with the catalytic site, and the C-terminal VNTR region. Also shown in this schematic figure is the N-terminal 
signalling peptide (green), bile salt-binding sites, site of phosphorylation, N- and O-glycosylation sites and the PEST sequence. 
The CEL protein presented here has 16 VNTR repeats, corresponding to the most common CEL variant in the general 
population. 
 
CEL is secreted from the acinar cells and is thought to follow the classical pathway of secretory proteins 
(Palade, 1975, Lombardo, 2001). The enzyme is appropriately folded, assembled and undergoes post-
translational modification during the secretion process from endoplasmic reticulum (ER). The protein 
is directed to the ER by its N-terminal signalling peptide. Here, asparagine at position 210 is N-
glycosylated, a modification that is thought to be essential for the secretion and expression of CEL 
(Abouakil et al., 1993, Bruneau and Lombardo, 1995, Lombardo, 2001). Next, the enzyme is transported 
to the Golgi apparatus with the help of a multiprotein complex that contains the chaperone GRP94 
(glucose-regulated protein with a size of 94 kDa) (Fig. 1.4 A) (Bruneau et al., 1995, Bruneau et al., 
2000). In the Golgi, CEL is heavily O-glycosylated at several threonine and serine positions (Rogers et 
al., 1986, Wang et al., 1995, Bruneau et al., 1997). Actually, the most common CEL protein with 16 
VNTR repeats is predicted to have a total of 36 O-glycosylation sites and, furthermore, 35 of these sites 
are located in the VNTR (NetOGlyc3.1). Once in the trans-Golgi area, CEL is released from the 
multiprotein folding complex upon phosphorylation, and further stored in zymogen granules (Fig.1.4 B) 
(Pasqualini et al., 2000, Verine et al., 2001). Incomplete or misfolded proteins are retained inside the 
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ER (Lodish et al., 2013). The N-terminal signalling sequence is cleaved from the protein during 
elongation, and is not present in the mature protein (Lodish et al., 2013).  
 
 
Figure 1.4 Acinar cell secretion of CEL. A) CEL is N-glycosylated in the ER lumen, and forms a complex with chaperone 
GRP94. The multiprotein complex is transported to the Golgi compartment where it is heavily O-glycosylated and 
phosphorylated. B) CEL is stored alone or in complex with GRP94 in zymogen granules until stimulation to be released into 
the small ducts. (Figures are adapted from, A: Secretory Granule Exocytosis (Burgoyne and Morgan, 2003), B: Digestive 
System from http://www.austincc.edu/apreview/PhysText/Digestive.html).  
 
The O-glycosylation plays an important role for the integrity of the CEL protein. It has been reported 
that proteins without O-glycosylation are less secreted and rapidly degraded (Bruneau et al., 1997). 
Furthermore, the VNTR is enriched in regions of proline, glutamate, serine and threonine, known as 
PEST sequences, and it has been suggested that O-glycosylation has a protective role by masking the 
PEST sequence, thereby prohibiting degradation of the enzyme (Rogers et al., 1986, Loomes et al., 1999, 
Lombardo, 2001, Raeder et al., 2006). This modification may also serve to protect the enzyme from 
proteolytic degradation after secretion to the intestine (Loomes et al., 1999).  
It is also possible that O-glycosylation is important for the solubility of the protein, by preventing non-
specific intramolecular interactions between hydrophobic areas exposed on the globular core, thus 
protecting the protein from self-associating (Loomes and Senior, 1997). Surprisingly, a complete 
truncation of the VNTR does not compromise or interfere with the enzymatic activity of CEL (Downs 
et al., 1994), but it may affect its interaction with bile salt (Hui and Howles, 2002).  
The enzyme activity of CEL is conferred by a catalytic amino acid triad of serine-histidine-aspartate, 
located within the globular domain of the enzyme (DiPersio et al., 1990). The enzyme activity is 
regulated by covering the active site with a loop structure, which associates with the protruding C-
terminal by hydrogen binding. When bile salt is present, it will bind to the loop, thereby exposing the 
active site for substrate binding (Wang et al., 1997, Moore et al., 2001, Hui and Howles, 2002). 
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1.3.3. The polymorphic nature of CEL   
Despite being conserved between species, the CEL gene has shown to be highly polymorphic. In 
addition to common single nucleotide polymorphisms (SNPs) that are present throughout the locus, and 
the VNTR length variation described above, mutations and copy number variants of the CEL locus have 
been reported (Raeder et al., 2006, McCarroll et al., 2008, Kidd et al., 2008, Torsvik et al., 2010, Fjeld 
et al., 2015). Some of these variants are described below and their protein structures illustrated in Figure 
1.5. The disease-causing variants are further described in section 1.4. 
A single-base deletion in the first repeat of the VNTR (CEL-DEL1) leads to diabetes and pancreatic 
exocrine dysfunction (Raeder et al., 2006). Another single-base deletion in the fourth repeat (CEL-
DEL4) has a similar but milder phenotype (Raeder et al., 2006). Both variants lead to frameshifts 
resulting in premature stop codons, and thus truncated protein variants with new C-terminal ends 
(Raeder et al., 2007). However, not all CEL deletions are pathogenic. A single-base deletion in the eighth 
repeat of the VNTR (CEL-DEL8) has been observed in the normal population.  
Single-base insertions are also commonly found in the CEL gene. These insertions result in truncated 
proteins, but has not yet been associated with disease (Raeder et al., 2006). One example is CEL-INS9, 
which has a single-base insertion in repeat 9. This leads to a frameshift and premature stop codon, also 
in repeat 9.  
During a study on suspected MODY families, one Danish patient with a CEL allele containing only 
three VNTR repeats was identified (CEL-3R) (Torsvik et al., 2010). 
CEL-HYB is a CEL deletion variant that recently was identified as a novel risk factor for chronic 
pancreatitis. CEL-HYB is formed by a fusion between CEL and CELP, and includes a VNTR from the 





Figure 1.5 Schematic overview of CEL protein variants. The illustration shows several CEL variants, their theoretical size 
and the length/composition of their VNTR domains. Blue boxes of the deletion variants illustrate the normal repeats, while 
orange boxes illustrate the downstream repeats as result of the frame-shifts. The red box in CEL-INS9 illustrates the 
downstream protein segment as result of a new reading frame. The yellow boxes in CEL-HYB illustrates the three VNTR 
repeats originating from CELP. 
 
All CEL variants shown in Fig. 1.5 have different amino acid compositions compared to the wild-type 
protein. All variants have also been observed in humans, except for CEL-TRUNC. The CEL-TRUNC 
variant was artificially constructed to analyse a CEL protein completely lacking the VNTR. This variant 




1.4. Pathogenic variants of CEL  
1.4.1. CEL-DEL1 (CEL-MODY)  
CEL-MODY follows an autosomal dominant pattern of inheritance and age of onset is typically 
childhood to young adulthood. The disease is characterized by pancreatic exocrine dysfunction and beta 
cell dysfunction (Raeder et al., 2006, Murphy et al., 2008, Torsvik et al., 2014). Patients suffering from 
CEL-MODY develop morphological abnormalities of the pancreas, such as lipomatosis, at an early age. 
These abnormalities may occur before the disease is noted on a clinical level (Raeder et al., 2006, Raeder 
et al., 2007, Bjorlykke et al., 2015). At later stages, the patients develop monogenic diabetes due to beta 
cell failure and pancreatic cyst formation (Raeder et al., 2014 ). Since CEL-MODY is a disease 
developing over time, studies on biomarkers can provide important information for prediction and 
treatment of the disease in the future (Raeder et al., 2007, Bjorlykke et al., 2015). 
CEL-MODY is caused by a single-base deletion in the VNTR region of the CEL gene. Such mutations 
were identified in two independent families with two separate single-base deletions in the first and the 
fourth repeat, respectively. As described before, these single-base deletions lead to frameshifts and 
premature stop codons in repeat 13, resulting in two truncated proteins denoted CEL-DEL1 and CEL-
DEL4 (Fig. 1.6) (Raeder et al., 2006). 
 
 
Figure 1.6 Overview of pathogenic MODY variants. The pathogenic variants CEL-DEL1 and CEL-DEL4 have the same 
globular domain as CEL-WT, but different VNTRs. The blue boxes illustrate normal VNTR repeats, while orange boxes 
illustrate the downstream repeats as a result of the frame-shifts.  
 
Compared to the normal protein with a theoretical size of 79 kDa, both CEL-DEL1 and CEL-DEL4 are 
reduced in size (73 kDa) (Fig. 1.6). Furthermore, there is a significant increase in the pI of CEL-DEL1 
compared to CEL-WT: pI = 9.5 vs pI = 5.2, respectively (Johansson et al., 2011). In a study performed 
by our group, CEL-DEL1 exhibited similar glycosylation, ubiquitination and secretion as CEL-WT, but 
displayed a high propensity to form both intra- and extracellular aggregates (Johansson et al., 2011). We 
have also found that after CEL-DEL1 secretion, there is a high degree of cellular reuptake and further 
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lysosomal degradation. Endocytosis of CEL-DEL1 resulted in reduced cell viability of both pancreatic 
acinar and beta cells, (Torsvik et al., 2014). Thus, based on these results, we have proposed that CEL-
MODY is a protein-misfolding disease due to a negative gain-of-function effect (Johansson et al., 2011). 
Interestingly, in a recent report they found that CEL-DEL1 causes ER stress, induction of the unfolded 
protein response (UPR), activation of NF-κB, and subsequent apoptosis (Xiao et al., 2016). In that study, 
the author suggests that intracellular accumulation of CEL-DEL1 overwhelms the cells` ER responsive 
stress mechanisms, and that apoptosis serves as a protection for the surrounding cells without activating 
further inflammation (Xiao et al., 2016).  
 
1.4.2. CEL-HYB 
Several copy number variants of CEL have been detected by our research group and others (McCarroll 
et al., 2008, Torsvik et al., 2010, Ragvin et al., 2013, Fjeld et al., 2015). However, we were the first to 
report that a hybrid variant of the CEL gene is a risk factor for chronic pancreatitis (Fjeld et al., 2015). 
The CEL hybrid is a deletion variant, which most likely has originated from non-allelic homologous 
recombination between CEL and its nearby pseudogene CELP, due to the high sequence similarity 
between the two genes (Fjeld et al., 2015). A proposed model of the recombination event is presented 
in Figure 1.7. 
Compared with healthy blood donor controls, we found that the carrier frequency of CEL-HYB was 
increased by >5-fold in patients with idiopathic CP from Germany and France. The CEL-HYB allele was 
also enriched in alcoholic chronic pancreatitis patients (Fjeld et al., 2015).  
The CEL-HYB gene includes only three VNTR repeats that originates from the CEL pseudogene (Fig. 
1.7 A, B). When expressed in cellular models, the CEL-HYB protein showed impaired secretion, 
intracellular accumulation and induced autophagy (Fjeld et al., 2015). The catalytic activity of CEL-
HYB was also reduced to about 40 % of the normal CEL enzyme activity. In contrast, the artificial CEL 
variant lacking the entire VNTR region (CEL-TRUNC) showed 90 % of wild-type enzyme activity. 
This implies that the reduction of CEL-HYB activity is due to an altered amino acid composition, rather 
than a truncated VNTR, and that increased enzyme activity is not part of the disease mechanism (Fjeld 
et al., 2015). 
CEL-HYB represents a new disease mechanism for chronic pancreatitis, as most pancreatitis genes are 





Figure 1.7 Schematic overview of CEL-HYB. A) A proposed model for how the CEL-HYB gene variant originated. Non-
allelic homologous recombination has taken place between CEL and CELP and the recombination region includes intron 10 as 
well as adjacent exon boundaries. B) Overview of CEL-HYB protein compared to CEL-WT protein. CEL-HYB has a truncated 
VNTR with only three repeats, originating from CELP. 
 
When comparing the disease mechanisms of CEL-HYB and CEL-MODY, they are different, as also 
indicated by their roles in pancreatic disease. CEL-MODY causes a dominantly inherited syndrome of 
exocrine and endocrine pancreatic dysfunction affecting all carriers with the mutation (Raeder et al., 
2006). In contrast, CEL-HYB is a risk factor for the development of chronic pancreatitis, although most 




1.4.3. CEL VNTR length polymorphisms in disease 
CEL VNTR length polymorphism has been associated with cholesterol profile of serum (Bengtsson-
Ellmark et al., 2004), rate of HIV-1 disease progression (Stax et al., 2012) and risk for alcohol-induced 
pancreatitis (Miyasaka et al., 2005). The latter association, however, could not be replicated in more 
recent and larger studies (Ragvin et al., 2013, Fjeld et al., 2016). Actually, one study is suggesting that 
CEL VNTR lengths are associated with alcoholic liver cirrhosis, and not alcohol induced pancreatitis 
(Fjeld et al., 2016). Also, one study set out to analyse the association between VNTR lengths and 
pancreatic cancer, but no association was found (Dalva et al., 2016). 
Given the unusually polymorphic nature of CEL, several unknown variants are likely to exist, and some 
of them possibly disease-causing. Also, it could be that some disease-associated CEL alleles are confined 
to certain populations (Molven et al., 2016b, Zou et al., 2016).  
 
1.5. The use of epitope tags in experimental research 
Epitope tags are easily detectable peptide sequences that can be introduced to proteins, simplifying 
experimental studies and protein purification (Hengen, 1995). The use of epitope tags can be exploited 
in immunoprecipitation, Western blot and immunocytochemistry. They are commonly used in studies 
of physical and functional properties of proteins, as well as their intracellular localisation. A protein is 
fused with an epitope tag by modifying the corresponding endogenous gene by recombinant DNA 
techniques (Kim et al., 2008).  
An epitope-containing protein is often referred to as a fusion protein, which refers to the end-to-end 
joining between the target protein and tag. Epitope tags can be fused with either the N- or C-terminal 
end of the protein, but can sometimes also be placed in the middle of the protein. Epitope tags are often 
divided into different classes, depending on their functions. They can roughly be divided into affinity 
and solubility tags. While affinity tags allow rapid and efficient purification, solubility tags enhance the 
solubility of a protein, and also proper folding (Malhotra, 2009). 
Several vectors containing epitope tag sequences exist, which can be fused with almost any protein. 
These tags range from just a few amino acids, to whole proteins or domains (Martinez-Ceron et al., 
2012). Some common short tags are: poly-His, poly-Arg, FLAG, c-myc, and strep-tag, while some 
common long tags are Glutathione S-transferase (GST) and Maltose-binding protein (MBP) (Table 1.2). 
In the case of short fusion tags, it is for most studies not needed to remove the tag after purification, as 
it will in most cases not affect the structure or function of the protein (Kosobokova et al., 2016). Proteins 
fused to large affinity tags such as Glutathione S-transferase and Maltose-binding proteins (Table 1.2) 
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can easily be purified from their biological source with affinity chromatography. These large tags do 
however need to be removed by proteases after purification (Terpe, 2003).  
Polypeptides consisting of several histidine residues are often used as epitope tags. They are small and 
have little effect on the charge or folding properties in the cell, or the structure and function of the mature 
protein (Mason et al., 2002, Carson et al., 2007, Li et al., 2013, Pajęcka et al., 2014). The 6xHis-tag has 
been constructed as an affinity tag. A recent study found that a 6xHis tag increased the expression level 
of their target protein compared to the untagged variant (Kosobokova et al., 2016). Another study 
showed that the fusion of an N-terminal epitope tag could alter the intracellular trafficking of human 
BST-2 (Lv et al., 2014). Furthermore, a study found that a His tag had a small negative effect on enzyme 
activity, and also an impact on the secondary structure of the protein (Chen et al., 2015). 
An ideal epitope tag should preferably be large and hydrophilic, and should, for easy detection, have an 
antibody recognition site in an area of the protein which is exposed. This often complicates the choice 
of epitope tag; as large epitope tags can interfere with the structure of the protein. In addition, exposed 
areas on the protein surface are often involved in the function of the protein (Sigma-Aldrich.). 
 
Table 1.2 Overview of common tags used in experimental procedures. Table is adapted from; Overview of tag protein 
fusions: from molecular and biochemical fundamentals to commercial systems (Terpe, 2003). 
 
  









3x FLAG DYKDHDGDYKDHDIDYKDDDDK 2.73
Calmodulin-binding peptide KRRWKKNFIAVSAANRFKKISSSGAL 2.96
Glutathione S-transferase Protein 26
Maltose-binding protein Protein 40
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2. Aims of the study 
The overall objective of this study was to understand more of the role of the CEL protein C-terminal in 
pancreatic disease. 
The specific aims of the project were: 
1. To investigate whether the presence of a C-terminal epitope-tag influences CEL protein 
expression, secretion and intracellular localisation in HEK293 cells 
2. To compare the expression, secretion and intracellular localisation of CEL variants differing in 
VNTR-length  
3. To investigate the effect of these CEL variants on cell viability and apoptosis in HEK293 cells 
4. To investigate the extent of putative O-glycosylation sites on CEL variants with varying VNTR-
lengths  





Table 3.1. DNA techniques 
 
 
Table 3.12. Plasmids 
 
 




Material Catalog number Supplier
Ampicillin A9518-5G Sigma-Aldrich
E.coli  OneShot® TOP10 chemically competent cells C404010-Aug2015 Invitrogen
Ethidium bromide (10 mg/ml) 161-0433 Life Technologies
Gel loading dye blue 70215S BioLabs
Lysogeny broth (LB) agar-ampicillin Q60120 Invitrogen
Lysogeny broth (LB) medium L7275-500TAB Sigma-Aldrich
Plasmid midi Kit (100) 12245 Qiagen
SeaKem® LE Agarose 500004 Lonz
Super optimal broth with catabolite repression (SOC) medium 15544-034 Invitrogen
1 Kb DNA Ladder N3232S BioLabs
Plasmids Description Supplier
pcDNA 3 CEL-DEL1 Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 CEL-DEL4 Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 CEL-DEL8 Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 Empty vector Addgene
pcDNA 3 CEL HYB Made in Bergen
pcDNA 3 CEL-INS9 Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 CEL-V562X Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 CEL-WT Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3 CEL-3R Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
pcDNA 3.1/V5-His B CEL-DEL1 Made in Bergen
pcDNA 3.1/V5-His B CEL-HYB Made in Bergen
pcDNA 3.1/V5-His B CEL-TRUNC Made in Bergen
pcDNA 3.1/V5-His B CEL-WT Made in Bergen
pcDNA 3.1/V5-His B Empty vector Invitrogen
Cell line Description Catalog number Supplier
HEK293 Human embryonic kidney cells 632180 Clontech
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Table 3.4. Reagents for cell culturing 
 
 
Table 3.5. Antibodies 
 
  
Material Catalog number Suppier
Antibiotic Antimycotic 15240062 Invitrogen
Dimethyl sulfoxide (DMSO) D8418-250ml Sigma-Aldrich
Dulbecco`s Modified Eagle`s Medium (DMEM) 41966-029 Gibco by Life Technologies
Fetal Bovine Serum (FBS) F7524-500ml Sigma-Aldrich
Lipofectamine 2000 Transfection reagent 11668-019 Invitrogen
OPTI-MEM (1x) Reduced Serum Medium 31985-062-100ml Gibco by Life Technologies
Dulbecco`s Phosphate Buffered Saline (PBS) D8537-500ml Sigma-Aldrich
Poly-L-Lysin P4832-50ml Sigma-Aldrich
0.05% Trypsin-EDTA 25300-054-100ml Gibco by Life Technologies
Antibody Catalog number Supplier Classification
Anti-CEL antibody (rabbit polyclonal) Gift Gift from Prof M.Lowe, Children`s 
hospital of Pittsburgh, USA
Primary
As20 anti-CEL antibody (mouse 
monoclonal)
Gift Gift from Prof O.Hernell, University 
of Umeå, Sweden
Primary
GAPDH antibody (V18) (goat polyclonal) sc-20357 Santa Cruz Biotechnologies Primary
Vanko anti-CEL antibody (rabbit 
polyclonal)
Gift Gift from Prof O.Hernell, University 
of Umeå, Sweden
Primary
V5 epitope tag antibody (mouse 
monoclonal)
R960-25 Invitrogen Primary
Donkey anti-goat IgG-HRP sc-2020 Santa Cruz Biotechnologies Secondary
Donkey anti-mouse IgG-HRP sc-2318 Santa Cruz Biotechnologies Secondary
Donkey anti-rabbit IgG-HRP sc-2305 Santa Cruz Biotechnologies Secondary
F(ab`)2 Goat anti-mouse IgG (H+L) 
secondary antibody Alexa Flour @ 488 
conjugate
A11017 Invitrogen Secondary
F(ab`)2 Goat anti-rabbit IgG (H+L) 





Table 3.6. Cell lysis, SDS-PAGE and Immunoblotting – products 
 
 
Table 3.7. Immunostaining 
 
 
Table 3.8. Mutagenesis 
 
  
Materials Catalog number Supplier
Amersham™ ECL™ prime western blotting detection reagent RPN2232 GE Healthcare
Blocking grade blocker nonfat-dry milk 170-6404 BioRad
BSA protein assay kit 23227 Pierce
Complete™ Mini EDTA-free protease inhibitors cocktail tablets 11836170001 Roche Diagnostics
Falcon™ Polystyrene Microplates (6 well plate) 08-772-29 Fisher-Scientific
Immobilion-P membrane, PVDF, 0.45 µm IPVH07850 Merck Millipore
Magic Mark XP western protein standard LC5603 Invitrogen
Methanol 67-56-1 Merck Millipore
NuPAGE® LDS sample buffer (4x) NP0007 Invitrogen
NuPAGE® MOPS SDS running buffer (20x) NP0001-02 Invitrogen
NuPAGE® Novex 10% Bis-Tris protein gels 1.0 mm NP0301BOX Invitrogen
NuPAGE® Sample reducing agent (10x) NP0009 Invitrogen
NuPAGE® Transfer buffer (20x) NP0006-1 Thermo Scientific
Phosphate buffer saline (PBS) Tablets 18912-014 Gibco
Pierce™ BCA protein assay kit 23227 Thermo Scientific
Precision Plus Protein™ dual colour standard 161-0374 BioRad
Restore™ Western blot stripping buffer 21059 Thermo Scientific
RIPA lysis buffer (10x) 20-188 Merck Millipore
Tween®20 8.22184.0500 Merck Millipore
Material Catalog number Supplier
Bovine serum albumin (BSA) A4503-100G Sigma-Aldrich
Cover slips (18mm) 117580 Werderop Werd
Falcon™ Polystyrene Microplates (12 well plate) 08-772-29 Fisher-Scientific
Gold antifade mounting reagent with DAPI P36935 Molecular Probes
Superfrost microscope slides Z692255-100EA Sigma-Aldrich
Normal goat serum 1000C Invitrogen
Paraformaldehyde (PFA) 818715 Merck Millipore
Phosphate buffered saline (PBS) D8537 Sigma-Aldrich
Saponin 47036-50G-F Sigma-Aldrich
Material Catalog number Supplier
DpnI  (10 U/µl) 200518-52 Agilent Technologies
PfuUltra HF DNA polymerase 200524-51 Agilent Technologies
QuikChange XL dNTP Mix 200516-52 Agilent Technologies
QuickSolution 200516-51 Agilent Technologies
XL 10-Gold Ultracompetent cells 200516-4-Aug2016 Agilent Technologies
XL 10-Gold 2-Mercaptoethanol 200314-43 Agilent Technologies
10X Reaction Buffer 200518-50 Agilent Technologies
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Table 3.9. Cell viability and apoptosis assay 
 
 
Table 3.10. De-glycosylation assay 
 
 
Table 3.11. Isoelectric focusing 
 
  
Material Use Catalog number Supplier
CellEvent Caspase-3/7 Green Detection Reagent Apoptosis assay C1042 Invitrogen
Cover slips (18mm) Apoptosis assay 117580 Werderop Werd
Falcon™ Polystyrene Microplates (12 well plate) Apoptosis assay 08-772-29 Fisher-Scientific
Superfrost microscope slides Apoptosis assay Z692255-100EA Sigma-Aldrich
CellTitre-Glo® Buffer Cell viability assay G756A Promega
CellTitre-Glo® Substrate Cell viability assay G755A Promega
96-Well Clear Bottom Plates Cell viability assay 29444-010 Corning®
Material Catalog number Supplier
Fisher chemical acetone 11369773 Fisher Scientific
O-Glycosidase (25 mU) 11365185001 Sigma-Aldrich
N-Glycosidase F (100 U) 11347101001 Sigma-Aldrich
Neuramidase (Sialidase) (1 U) 11080725001 Sigma-Aldrich
Material Catalog number Supplier
Novex® IEF Sample Buffer pH 3-10 (2X) LC5311 ThermoFisher Scientific
Novex™ pH 3-10 IEF Protein Gels, 1.0 mm, 10-well EC6655BOX ThermoFisher Scientific
Novex® IEF Anode Buffer (50X) LC5300 ThermoFisher Scientific
Novex® IEF Cathode Buffer pH 3-10 (10X) LC5310 ThermoFisher Scientific
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Table 3.12. Buffers and solutions 
 
 




Buffers and solutions Use Composition
1x RIPA lysis buffer Cell lysis 10x RIPA lysis buffer (0.5M Tris-HCl, pH 7.4, 1.5M 
NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM 
EDTA.) in 10 mlddH2O + 1 tablett Complete™ Mini 
EDTA-free protease inhibitors cocktail tablet 
Agarose gel Gel electrophoresis 1% (w/v) Seakem/agarose dissolved in 1xTBE buffer 
pH 8.3 with EtBr (10 mg/ml)
TBE buffer (pH 8.3) Gel electrophoresis Tris-borate (45 mM)/EDTA (1 mM) 
NuPAGE® transfer buffer (1x) Immunoblotting NuPAGE® transfer buffer (20x) in ddH2O and 10 % 
Methanol
PBS-tween (0.05 %) Immunoblotting Phosphate buffered saline tablet (pH 7.45) and Tween® 
20 dissolved in ddH2O
Blocking buffer Immunofluorescence 0.2% BSA, 0.2% Saponin, 5% normal goat serum in 
PBSFixative Immunofluorescence 6% PFA + 0.2 M PB pH 7.2 (1:1)
Paraformaldehyde (PFA) 
solution
Immunofluorescence 6% (w/v) PFA solution, 3 g PFA dissolved in 50 ml 
ddH2O + 5 drops 1 M NaOH
Quenching solution Immunofluorescence 50 mM NH4Cl in PBS
Washing buffer Immunofluorescence 0.2% BSA in PBS
Washing buffer saponine Immunofluorescence 0.2% BSA and 0.2% Saponin in PBS
0.2 M Phosphate buffer (PB) Immunofluorescence 0.2 M Na2HPO4 and 0.2 M NaH2PO4 adjusted to pH 7.2 
Denaturation buffer Isoelectric focusing 20 mM phosphate buffer, 1% (w/v) SDS, 1% (v/v) beta-
mercaptoethanol in ddH2O
Incubation buffer Isoelectric focusing 20mM EDTA, 100mM phosphate buffer, 0.5% (v/v) 
Nonidet P-40, 1% (v/v) beta-mercaptoethanol in ddH2O 
NuPAGE® MOPS SDS running 
buffer (1x)
SDS-PAGE NuPAGE® MOPS buffer (20x, 50 mM MOPS, 50 mM 
Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7) in ddH2O 
NuPAGE® Transfer buffer (1x) SDS-PAGE 50 ml NuPAGE® Transfer buffer (20x) in 950 ml ddH2O
Instrument Manufacturer
Eppendorf Centrifuge 5417C A/B Phil
Heragus Multifuge 3S-R Thermo Electron Corporation
Infinite M200Pro luminomenter Tecan
Innova 4300 Incubation shaker Dipling HOUM New Brunswick Scientific
LAS-1000 imager Fujifilm
Leica Confocal SP5 Leica Microsystems
Megafuge 1.0 R Heraeus Seoatech
Molecular Imager® Gel Doc™ XR system BioRad
NanoDrop ND-1000 Saveen Werner
Scepter handheld automated cell counter Merck Millipore
27 
 





Image Reader LAS-100 Pro v2.6 Fujifilm
Leica Application Suite v2.0 Leica Microsystems
Microsoft Office 365 Microsoft Corporation
Photoshop Adobe Photoshop CC
QuantityOne Biorad




4.1. Plasmid preparation and evaluation of DNA quality  
4.1.1. Transformation of OneShot® TOP10 chemically competent E.coli cells  
Transformation was performed by applying the heat shock method as described by the manufacturer’s 
instructions (Invitrogen). cDNAs encoding the CEL variants to be analysed in this study, were cloned 
into either a pcDNA3 (Addgene) or pcDNA3.1/V5-His (Invitrogen) vector backbone. In short, 1 µl 
(300-1000 ng) of plasmid was added to a vial (50 µl) of OneShot® TOP10 chemically competent E.coli 
cells. After incubation on ice for 30 min, the cells were subjected to heat shock (42°C) for 30 s and 
directly transferred to ice. SOC medium (250 µl) was added to each vial, and incubated 1 h with shaking 
(200 rpm at 37°C). The cells were spread onto agar plates containing ampicillin (100 µg/ml), and 
incubated o/n at 37°C. 
 
4.1.2. Plasmid preparation 
A single colony was inoculated in starting cultures with LB medium (5 ml) containing ampicillin (100 
µg/ml). The cultures were incubated for 8 h at 37°C with shaking at 250 rpm. Next, starting cultures 
were diluted according to the protocol for high copy plasmids; 1:500 in LB medium containing 100 
µg/ml ampicillin and grown o/n. Plasmid purification was performed according to the Qiagen® Plasmid 
Midi Kit (100) protocol.  
 
4.1.3. Determination of plasmid yield and quality 
The concentration and quality of the purified plasmids were determined by OD measurements and 
agarose gel electrophoresis.  
 
4.1.3.1. OD measurements 
We measured the absorbance of 1 µl DNA at 260 nm by a NanoDrop spectrophotometer. To assess the 
purity of the DNA, the 260/280 nm absorbance ratio was considered. This ratio should be approximately 
1.8. Free nucleotides, RNA, single stranded DNA, and double-stranded DNA all absorb at of 260 nm 
and will contribute to the total absorbance measured in the sample. A ratio of approximately 1.8 is 
considered as a pure DNA sample. A lower ratio could indicate a contamination of protein, phenol or 
other molecules that absorb near 280 nm, while a higher ratio indicates RNA contamination. 
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The 260/230 absorbance ratio is a secondary measurement of the quality of the DNA. This value is often 
higher than the 260/280 ratio, and should range between 2.0-2.2 to be considered pure. A lower 
absorbance ratio could indicate contaminants that absorb near 230 nm, such as residual phenol- or 
guanidine residues. 
 
4.1.3.2. Agarose gel electrophoresis 
For verification of plasmid quality, all CEL variants were separated on a 1% agarose gel, containing 0.5 
µg/ml ethidium bromide, to visualize the DNA migration in the gel. A total of 1 µl (300-1000 ng) of 
each plasmid was used. This volume was adjusted to 10 µl by adding ddH2O, and 2 µl of 6x loading 
buffer. The samples were run adjacent to a molecular-weight size marker at 100 V in TBE buffer for 1.5 
h. Molecular Imager® Gel Doc™ XR system was used for documentation. 
 
4.2. Constructing a CEL-HYB plasmid without an epitope tag 
A stop codon was introduced into the pcDNA3.1/V5-His-CEL-HYB plasmid using the QuikChange site 
directed mutagenesis kit (Agilent Technologies). This plasmid contains an XhoI restriction site directly 
after the CEL-HYB cDNA, before the epitope tag sequence. The stop codon was created in this XhoI 
restriction site (see Fig. 5.1). 
 
4.2.1. Primer design and mutagenesis 
The primers needed for mutagenesis were constructed using Agilent Technologies QuikChange Primer 
Design.  
Both primers were diluted to a 100 µM stock solution in TE-buffer. The primers were kept at -20°C 
until use. The mutagenesis was performed according to the protocol included in the QuikChange II XL 
Site-Directed Mutagenesis kit. 
A PCR reaction mix was prepared in a tube as described in Table 4.1. The tube was mixed and briefly 





Table 4.1. Master mix components for the site directed mutagenesis kit. 
 
 
Table 4.2 Thermal amplification cycles for mutagenesis.  
 
4.2.2. DpnI digestion 
To remove parental non-mutated supercoiled dsDNA, DpnI digestion was performed. DpnI restriction 
enzyme (1 µl, 10 U/µl) was added directly to the PCR reaction tube. The tube was mixed, spun down 
for 1 min and immediately incubated for 1 h at 37°C. The plasmid was further transformed according to 
the manufacturer’s (Agilent technologies) protocol for transformation of XL-10 GOLD Ultra competent 
cells. 
The competent cells (45 µl) were thawed on ice before being added 2-mercaptoethanol (2 µl). The tube 
was incubated on ice for 10 min, with gentle swirling every 2 min. The DpnI treated DNA was added 
(2 µl) to the competent cells and incubated for 30 min on ice, before heat shocked at 42°C for 30 sec. 
Preheated LB medium (500 µl) was added to the tube and incubated for 1 h at 37°C. Subsequently, the 
cells were centrifuged at 2000 rpm for 2 min, and 300 µl of the supernatant removed. The cells were 
resuspended, plated on agar plates containing ampicillin (100 µg/ml) and incubated o/n at 37°C. 




DNA template (10 ng/µl) 4
dNTP mix 1
Forward primer (20 µM) 0.7
Reverse primer (20 µM) 0.7
Pfu ultra HF DNA-polymerase 1
QuickSolution 3
10x reaction buffer 5
Total volume 51
Step Temperature (°C) Time Number of cycles
Initial denature 95 1 min 1
Denature 95 50 sec
Annealing 69 50 sec 18
Extension 68 7.5 min




4.2.3. Sequencing of CEL-HYB 
The new CEL-HYB construct without tag was verified by Sanger sequencing. Sequencing was performed 
using 0.5 µg of DNA in a reaction mix (Table 4.3) with various primers for the CEL gene (Table 4.4). 
Thermocycling was performed on a GeneAmp PCR System 9700 from Life Technologies according to 
conditions listed in Table 4.5. 
 
Table 4.3 Components for sequencing of CEL variants.  
 
 
Table 4.4 Primers used for sequencing of CEL variants.  
 
 






Betain (5 µM) 2
BigDye® terminator v1.1 ready reaction mix 1
Primer (20 µM) 0.25
Template/ddH2O 4.75
5x sequencing buffer 2
Total volume 10
Primer Target DNA DNA target sequence
BF (FWD) Exon 2 GAAGCTGGGCGCC
BGH (REV) BGH polyadenylated sequence ATCTTCCGTGTCAGCTCC
BR (REV) Exon 6 CATCCGGCGA
CF (FWD) Exon 4 TCACCTTCAA
CR (REV) Exon 8 GAAAGTCACGGAGGAG
DF (FWD) Exon 8 CCGCCGACATCGACTA
EF (FWD) Exon 11 ACACACTGGGAACCCT
T7 (FWD) T7 promotor ATTATGCTGAGTGATATCCC
Step Temperature (°C) Time Number of cycles
Initial denature 96 10 min 1
Denature 96 10 sec
Annealing 58 5 sec 25




4.3. Cell cultures and transfection 
4.3.1. Culturing 
Human embryonic kidney, HEK293 cells were cultured in Dulbeccos Modified Eagle`s Medium 
(DMEM) with high glucose (4500 mg/L) supplemented with 10% Fetal Bovine Serum (FBS) and 100 
U/ml of Antibiotics Antimycotic (AA) in humidified atmosphere with 5% CO2 at 37°C. Cell culturing 
was done under sterile conditions, and the cells were grown in T75 cm2 flasks during all experiments 
unless stated otherwise.  
 
4.3.2. Sub-culturing and seeding 
For passaging of cells, growth medium was removed and the cells were washed with pre-warmed PBS. 
The cells were added 0.5 ml (T25 cm2) or 1 ml (T75 cm2) of 0.05 % Trypsin-EDTA until they detached 
from the surface. The cells were re-suspended in DMEM, and an appropriate dilution of cells were 
transferred to a new T75 cm2 flask, and filled up to 13 ml with medium. For experiments requiring an 
exact number of cells, the re-suspended cells were transferred to a 15 ml Falcon tube, diluted in PBS 
and counted with a handheld Sceptre automated cell counter. For all experiments presented in this study, 
the cell passage number was kept from 11 to 30. 
 
4.3.3. Freezing and thawing 
A vial of 1 ml frozen HEK293 cells was rapidly thawed and the cells were resuspended in 5 ml of pre-
warmed DMEM before being transferred to a T25 cm2 flask. The following day, medium was removed 
and replaced with fresh growth medium to remove debris, dead cells and traces of DMSO.  
To freeze the cells, they were grown to 80-90% confluency in a T75 flask. Next, the cells were washed 
with PBS, trypsinated and re-suspended in 5 ml of DMEM. The cells were centrifuged for 4 min at 1000 
rpm and the medium (supernatant) removed. The cell pellet was re-suspended in 5 ml freezing medium 
(10% DMSO, 50% FBS and 40% DMEM) and aliquoted into cryo vials. The vials were placed in a 
container with isopropanol at -80°C for minimum 24 h and transferred to a nitrogen tank for long term 
storage. 
 
4.3.4. Transient transfection of HEK293 cells 
Cells were seeded in 6-well plates (4 x 105 cells per well), 12-well plates (2 x 105 cells per well) or 96-
well plates (1500 cells per well) and grown to 60-70 % confluency prior to transfection. Transfection 
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was performed using Lipofectamine® 2000 according to the manufacturer’s instructions (Fig. 4.1). For 
each transfection, the total amount of DNA was 4 µg in 6-wells, 0.5 µg in 12-wells and 0.1 µg in 96-
wells. Both Lipofectamine® 2000 and DNA was diluted in OptiMem medium and incubated for 5 min 
at room temperature (RT) before mixed at a ratio of 1:1. The DNA-lipid mix was incubated for 20 min 
at RT before added to the cells. The cells were incubated for 4-6 h before the medium was replaced with 
fresh growth medium and left to grow for 24, 48 or 72 h before further analysis.  
 
 
Figure 4.1 Timeline for transfection with Lipofectamine 2000 of HEK293 cells. Figure adapted from Lipofectamine® 2000 
Reagent protocol. 
 
4.4. Preparation of analytical fractions: cell lysate, cell pellet and medium 
48 or 72 h post transfection, cells grown in 6-wells were prepared for cell fractionation. The medium 
was collected and centrifuged at 14 000 g for 5 min. The supernatant was removed and kept for further 
analysis (medium fraction). The cells were washed once with PBS and added 150 µl of ice-cold RIPA 
lysis buffer containing a cocktail of protease inhibitors (1 tablet per 10 ml of 1x RIPA buffer). The cells 
were collected using a cell scraper and the lysate incubated for 30 min on ice before centrifugation at 20 
000 g for 15 min. Again, the supernatant was removed and kept for further analysis (lysate fraction). 
The pellet was washed with 150 µl of PBS and centrifuged at 20 000 g for 15 min two times. Finally, 
the pellet was added 100 µl of 2x LDS sample buffer with reducing agent and stored at -80°C until 
further analysis (pellet fraction).  
 
4.4.1. Protein concentration determination 
The protein concentration was determined for all samples prior to SDS-PAGE and immunoblotting, 
using the Pierce™ BCA Protein Assay Kit. A total of 5 µg protein from the lysate fraction was used for 
SDS-PAGE sample loading. The equivalent volume was used from the medium fraction, assuming a 
correlation between the amount of protein in lysate and medium fractions.  
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4.5. SDS-PAGE and immunoblotting 
The cell lysate and medium samples were prepared with a total volume of 20 µl (Table 4.6). The samples 
were denatured on a heating block at 56°C for 15 min, while the pellet samples were denatured for 95°C 
for 15 min. The samples were loaded on a 10% NuPage Bis-Tris gel (1 mm) and separated by 
electrophoresis. For all medium and lysate samples, 20 µl was loaded, while 3-5 µl was loaded for the 
pellet samples. Four µl of Precision Plus Protein™ Dual Colour Standards marker and 2 µl of Magic 
Mark XP Western Protein Standard were loaded on the gels. The gels were run in 1x NuPage MOPS 
buffer at 90 V for 15 min, and then at 180 V for 1 h.  
 
Table 4.6 Components for SDS-PAGE sample preparation for lysate and medium samples.  
 
 
Western Blotting was performed with semi-wet blotting of NuPage® gels in XCell Blot Module 
chambers according to the manufacturer’s instructions. Proteins were transferred to a Polyvinylidene 
fluorid (PVDF) membrane, which was activated in methanol for 1 min prior to use. The electro blotting 
procedure was performed at 30 V for 1 h in NuPage transfer buffer with 10% methanol. The membrane 
was then blocked in 5% dry milk either overnight at 4°C or for 1 h at RT. The membrane was incubated 
with the primary antibodies anti-V5 (1:20 000) or anti-CEL (1:10 000) at 1 h at RT or o/n at 4°C to 
detect the recombinant CEL proteins. The anti-GAPDH (1:1000) antibody was used for determining the 
amount of GAPDH protein as loading control. All antibodies were diluted in 1% dry milk in PBS-
Tween. The membrane was washed 3 x 5 min with PBS-Tween (0.05 %) and further incubated with 
HRP-conjugated secondary antibodies for 1 h at RT. All secondary antibodies were diluted 1:5000. The 
membrane was washed 1x 15 min and 3x 5 min with PBS-Tween before being developed with an ECL 
Western Blotting kit. The signals were analysed using a Las 1000 imager. 
 
4.6. Immunostaining 
Cells seeded in 12-well plates on coverslips coated with Poly-L-lysine were transiently transfected and 
analysed with immunostaining 48 h post transfection. The cells were washed twice with pre-warmed 
PBS and fixed in pre-warmed 3% paraformaldehyde (pH 7.2) for 30 min. Then, the cells were washed 
twice with washing buffer (WB), before treatment with quench solution for 15 min to remove unreacted 
Component Volume (µl)
Reducing agent (500 mM dithiothreitol (DTT)) 2
Sample/ddH2O 13




aldehyde groups. For permeabilization, the cells were treated with blocking buffer (BB) for 30 min. 
Next, the cells were washed three times with WB-saponin and incubated with primary antibody (1:200 
in BB) for 2 h at RT. The cells were further washed quickly three times with WB-saponin, followed by 
2 h washing at RT on a shaker with subsequent buffer changes. The samples were incubated with Alexa 
Fluor 488 or Alexa Fluor 594 conjugated secondary antibodies for 1 h at RT. After a final triple washing 
with WB-saponin, the cells were washed twice with PBS, and mounted on glass slides with 10 µl of 
Prolong Gold Antifade Solution with DAPI. The results were evaluated and images collected with an 
SP5 AOBS confocal microscope. 
For double staining, the protocol described above was repeated. Thus, after the last wash with WB-
saponin, the cells were incubated with blocking buffer again for 30 min – then incubated with a new 
primary and secondary antibody. 
 
4.7. Cell viability assay 
HEK293 cells were seeded in 96-well plates and transfected as described above (section 4.3.4), and cell 
viability was evaluated 48 h post transfection. To determine the number of cells needed for 60-70 % 
confluency at the day of transfection, a cell titration was carried out with a 96-well plate. Cells were 
seeded from 500 to 2000 cells per well, to evaluate the optimal number of cells to use for detection with 
CellTitre-Glo®. The wells containing 1500 cells was found to be the most optimal after 48 h of growth 
and was used for further experiments. Measurements showed that 20 µl of medium would evaporate 
after 48 h, and so 120 µl of medium was added to the cells, leaving 100 µl which was required for 
detection 48 h post transfection.  
Cell viability was measured using the CellTiter-Glo® Luminescent Cell Viability kit (Promega), 
following the manufacturer’s instructions (Fig. 4.2). Both cells and reagents were left in RT for 30 min 
before treatment with equal amounts of reagents, 100 µl of CellTitre-Glo®-solution was added to the 
cells. Before detection, the 96-well plates were subjected to 2 min of shaking and 10 min of 
destabilization. The luminescent signal was detected with a Tecan Infinite M200PRO luminometer. 
The number of viable cells in the plate is determined by measuring the presence of ATP, which indicates 
metabolically active cells. Luciferase generates a luminescent signal in the presence of ATP, Mg2+ and 
molecular oxygen by converting luciferin to oxyluciferin and light. By addition of the CellTitre-Glo® 
reagent, the luminescent signal is proportional to the ATP present, which in turn is directly proportional 





Figure 4.2 Timeline for cell viability assay. Figure adapted from CellTiter-Glo® Luminescent Cell Viability Assay protocol. 
 
4.8. Apoptosis assay 
HEK293 cells were seeded and transfected as described above in section 4.3.4. After 48 h, growth 
medium was removed to leave a volume of 250 µl per well. One µl of CellEvent™ Caspase-3/7 Green 
Detection Reagent (final concentration 7.5 µM) was added to the cells, and incubated at 37°C for 30 
min. The cells were washed twice with PBS, fixed in 3 % PFA and washed twice. The coverslips were 
mounted in 10 µl of Prolong Gold Antifade Solution with DAPI and analysed by confocal microscopy 
as described above. Apoptotic cells were visualized and identified by their green nuclei.  
The Caspase-3/7 Green Detection Reagent is a four-amino acid peptide (DEVD), containing a cleaving 
site for Caspase-3/7, and is bound to a DNA-binding dye with an absorption maximum of 502-530 nm. 
The DNA-binding dye is non-fluorescent as it cannot bind to DNA due to inhibition from the DEVD 
peptide. However, in apoptotic cells, Caspase-3/7 is activated and the DEVD peptide is cleaved off, 





4.9. Statistical analysis 
All statistical analyses were conducted by two-tailed student t-tests. The statistical calculations were all 
carried out using the Excel program of the Microsoft Office software package. P-values < 0.05 were 
considered as statistically significant. 
 
4.10. De-glycosylation assay 
Cell growth medium (100 µl) was collected from transiently transfected HEK293 cells, 48 h post 
transfection. The medium was acetone-precipitated (medium/acetone 1:5) at -20°C for 30 min, and the 
proteins collected by centrifugation at 18000 g for 30 min at 4°C. The acetone was removed by carefully 
pipetting off the solution, and the pellet was allowed to dry at 37°C for 5 min. The proteins were re-
suspended in 25 µl of denaturation buffer, and incubated at 100°C for 10 min. Next, 125 µl incubation 
buffer was added to the proteins. The proteins were treated with three different glycosidase enzymes; 2 
units of N-glycosidase F and/or 2.5 milliunits of O-glycosidase and/or 5 milliunits of α2-3,6,8,9 
Neuraminidase (Sialidase). The samples were digested on shaking (300 rpm) overnight at 37°C, and 1:5 
acetone-precipitation was repeated. The pellets were resuspended in 2x LDS loading buffer and 
denatured at 95°C for 10 min, before analysis by SDS-PAGE and immunoblotting as described above. 
 
4.11. Isoelectric Focusing 
Cell growth medium (5 µl) was collected from transiently transfected HEK293 cells, 48 h post 
transfection, and 10 µl samples were prepared by adding 5 µl of 2x IEF Sample buffer (pH 3-10). To 
prepare 1x IEF Anode- and Cathode buffer, 20 ml of 50x IEF Anode buffer was added to 980 ml of 
ddH2O, and 20 ml of IEF Cathode buffer was added to 180 ml of ddH2O. Both buffers were kept at 4°C 
until use. The 10 µl samples were loaded on the gels, and the inner buffer chamber was filled with chilled 
1x IEF Cathode buffer, while the outer chamber was completely filled with chilled 1x IEF Anode buffer. 
The gel was run for 1 h at 100 V, 1 h at 200 V and for 30 min at 500 V. The gel was further equilibrated 
in 0.7 % acetic acid for 10 min, and Western blot was performed. Western blot was performed as 
described previously, however with 0.7 % acetic acid as transfer buffer, and the gel/membrane sandwich 






5.1. Construction of a CEL-HYB plasmid without the V5/His tag 
To make a plasmid that expressed the human CEL-HYB gene without a tag, we introduced a stop codon 
into our already existing pcDNA3.1/V5-His-CEL-HYB construct. The stop codon was introduced by 
site-directed mutagenesis after CEL exon 11 but before the V5/His sequence, as illustrated in Fig. 5.1. 
The new stop codon was verified by sequencing. Furthermore, we sequenced through the entire new 
CEL-HYB cDNA using primers covering CEL as well as vector sequence boundaries to make sure that 
the construct was correct and in frame.  
Figure 5.1 Sequence of CEL-HYB after introduction of stop codon in CEL-HYB-V5/His. Depicted in the figure is CEL-
HYB exon 11. The XhoI site (blue) and V5/His sequence (green) are shown, followed by a stop codon (purple). A two-base 




5.2. Plasmid purification and determination of DNA purity 
In addition to OD measurements for estimating DNA concentration and quality, all plasmids used in this 
project were separated on a 1 % agarose gel to confirm that the preparation procedure had been 
successful, and that the plasmids were intact. The high molecular bands seen in Figure 5.2 are likely 
open circular plasmids while the low molecular bands are the intact, supercoiled plasmids. 
 
Figure 5.2 Plasmid verification by agarose gel electrophoresis. A total of 1 µl (300-1000 ng) of the different CEL plasmids 




5.3. The effect of the C-terminal V5/His-tag on CEL protein expression and secretion  
5.3.1. Western blot analysis 
To investigate whether the C-terminal V5/His tag has an effect on CEL protein expression and secretion, 
HEK293 cells were transiently transfected with plasmids expressing CEL-WT, CEL-DEL1, or CEL-
TRUNC with and without tag. Cells transfected with empty vector (EV) was included as a negative 
control. After 48 h of transfection, cell medium, lysate and pellet fractions were isolated and analysed 
by SDS-PAGE and Western blotting. Immuno-detection was performed using either the anti-CEL 
(Pittsburgh) or anti-V5 antibodies. GAPDH was used as loading control.  
Detection with the anti-CEL (Pittsburgh) antibody is seen in the left panel of Figure 5.3. An unspecific 
band appeared for all variants at approximately 70 kDa in the same fraction (this unspecific band has 
been observed by others in our research group as well as by our collaborators in Pittsburgh who 
developed the antibody). For several of the variants, we also detected two or more bands. These bands 
are likely to be differently matured forms of CEL, either fully glycosylated (bands with higher molecular 
weight) or partially glycosylated (lower bands) proteins (Johansson et al., 2011, Fjeld et al., 2015). For 
CEL-TRUNC, these are likely different isomers of N-glycosylation, as CEL-TRUNC contains only the 
four first amino acids of the VNTR and no C-terminal O-glycans. 
All variants were detected in the lysate fraction, however, the untagged CEL variant had stronger signals 
compared to the V5/His tagged variants. CEL-WT displayed a slightly stronger band compared to CEL-
DEL1 and CEL-TRUNC. 
The trend in the pellet fraction was similar to the lysate: all V5/His tagged variants showed a lower 
expression than their untagged counterparts. However, we did not observe any band for CEL-WT-
V5/His, and CEL-TRUNC had a very strong signal, both when compared to its tagged counterpart and 
to the other variants. We also detected different glycosylated variants of CEL in the pellet.  
All variants could be detected in the medium. Both untagged and tagged variants of CEL-WT and CEL-
DEL1 were secreted at similar levels, while both variants of CEL-TRUNC showed weak bands. Except 
for CEL-TRUNC, all variants showed only one band, which is likely to correspond to the fully 
glycosylated form of the proteins.  
Detection with the anti-V5 antibody (right panel) resulted in a faint band for CEL-WT-V5/His in the 
pellet fraction. CEL-DEL1-V5/His and CEL-TRUNC-V5/His clearly had weaker bands than CEL-WT-
V5/His in medium fraction. This blot also confirmed that only the V5/His-tagged variants of CEL were 




Figure 5.3 Expression, distribution and secretion of tagged versus untagged CEL-variants in various fractions of 
HEK293 cells. Cells were transiently transfected with plasmids encoding CEL-WT, CEL-DEL1 and CEL-TRUNC with or 
without the V5/His tag. Lysate, pellet and medium fractions were analysed by SDS-PAGE and Western blotting using a CEL-
specific antibody (Pittsburgh) or anti-V5 antibody. GAPDH was used as loading control. The results shown are representative 
of three independent experiments. 
 
We also analysed the effect of the V5/His tag on the CEL-HYB variant. Due to the need of constructing 
a CEL-HYB plasmid without tag, this experiment was performed at a later stage than for the variants 
above. However, we also included CEL-WT in this experiment, as a control. The result can be seen in 
Figure 5.4. 
With the anti-CEL antibody (Pittsburgh - left panel) we observed the same unspecific band in the lysate 
(70 kDa) as shown in Figure 5.3. Both CEL-HYB variants were detected in this fraction and the tagged 
HYB protein appeared in different modified forms. In the pellet, we could observe strong bands for the 
CEL-HYB variants, as well as higher molecular forms of the proteins. In contrast, hardly any CEL-HYB 
was seen in the medium. Actually, no band was observed for the CEL-HYB variant without a tag. 
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With the anti-V5 antibody, CEL-HYB was detected in all fractions, but the amount was reduced in the 
lysate compared to the pellet and medium fractions. Compared to the anti-CEL antibody, the anti-V5 
antibody recognized the CEL-HYB-V5/His protein to a much higher degree. As for CEL-WT proteins, 
the expression patterns observed were basically the same as in Figure 5.3, except that CEL-WT-V5/His 
was now detected in the pellet. This may be due to less protein loaded to the SDS-PAGE represented in 
Figure 5.3 compared to Figure 5.4 (3 µl vs 5 µl, respectively). 
 
Figure 5.4 Expression, distribution and secretion of epitope tagged versus untagged CEL-HYB and CEL-WT variants 
in various fractions of HEK293 cells. Cells were transiently transfected with CEL-WT and CEL-HYB with or without the 
V5/His tag. Lysate, pellet and medium fractions were analysed by SDS-PAGE and Western blotting using the CEL-specific 





5.3.2. Immunostaining and confocal analysis 
Immunostaining and confocal imaging were performed to study the intracellular localisation of CEL-
WT, CEL-DEL1, CEL-TRUNC and CEL-HYB, and to compare possible effects of the conjugated 
V5/His tag. HEK293 cells were transiently transfected and the cells subjected to immunostaining 48 h 
post transfection. Both tagged and untagged variants of CEL were detected with the CEL-specific 
antibodies. Cells transfected with empty vector were used as a negative control (data not shown).  
In summary, we observed a stronger intracellular signal for CEL-WT, CEL-DEL1 and CEL-TRUNC 
without tag compared to their tagged counterparts (Fig. 5.5 A). We also found that there was a much 
stronger intracellular signal of CEL-DEL1 compared to both CEL-WT and CEL-TRUNC, whereas 
CEL-TRUNC showed a stronger signal than CEL-WT (Fig. 5.5 A). As for CEL-HYB, it was observed 
that the intracellular staining was equally strong for both the untagged and tagged variant (Fig. 5.5 B). 
However, no conclusions can be drawn about subcellular localisation based on the results presented in 







Figure 5.5 Intracellular localisation of epitope tagged and untagged CEL variants in HEK293 cells. The cells were 
subjected to immunostaining 48 h post transfection. The As20 antibody was used to detect the CEL-HYB variants whereas the 
Vanko antibody was used for all other variants. The secondary antibodies used were AlexaFlour 488 (green) and AlexaFlour 
594 (red), respectively. A) Cells transfected with plasmids encoding CEL-WT, CEL-DEL1 and CEL-TRUNC with and without 
the V5/His tag. The results shown are representative of three independent experiments. B) Cells transfected with plasmids 




5.4. The effect of CEL VNTR length on protein expression and secretion 
5.4.1. Western blot analysis 
In this study, we transfected cells for both 48 h and 72 h. The latter transfection time was selected to 
compare our results more directly with the data of Xiao et al., 2016. We only used untagged constructs. 
HEK293 cells were transiently transfected with plasmids encoding CEL-WT, CEL-DEL1, CEL-DEL4, 
CEL-DEL8, CEL-TRUNC, CEL-3R, CEL-INS9 and EV, to investigate and compare the protein 
secretion of the different variants. Cell fractionation was performed as described in section 5.3.1. The 
fractions were analysed by SDS-PAGE and Western blot, and detected with the anti-CEL antibody 
(Pittsburgh) and GAPDH as a loading control (Fig. 5.6).  
For both 48 and 72 h transfection, all variants could be detected in the different fractions. However, the 
amount of CEL protein in each fraction varied between variants, and with the transfection time. When 
detecting with the anti-CEL antibody (Pittsburgh), the same unspecific band seen in Figure 5.3 appeared 
for all variants at approximately 70 kDa in the lysate fraction. In addition, we detected two or more 
bands for several variants. Again, these are likely to be differently post-translational N- and O-
glycosylated forms, as previously reported (Johansson et al., 2011, Fjeld et al., 2015).  
All variants were detected in the lysate fraction. We also observed that all variants except CEL-DEL1 
were present as two bands. Also, we observed weaker bands for the disease-causing variants CEL-DEL1 
and CEL-DEL4 in the lysate fraction. These bands were weaker after 72 h transfection compared to the 
48 h transfection. CEL-TRUNC appeared as equally weak as CEL-DEL1 and CEL-DEL4 after 72 h, 
despite a very strong band in the 48 h transfection. In addition, the unspecific band appearing for all 
variants at approximately 70 kDa in the lysate fraction was generally observed as weaker or absent after 
72 h of transfection.  
Although not as prominent as for the lysate fraction, we did observe stronger band for all variants 
compared to CEL-WT in the pellet fraction, after both 48 and 72 h transfection. Also, we observed that 
some of the variants migrated as different glycosylated variants of CEL in the pellet. 
Less amounts of CEL-TRUNC and disease-causing variants CEL-DEL1 and CEL-DEL4 were observed 
in the medium fraction, while variants CEL-DEL8, CEL-3R and CEL-INS9 seemed to be secreted to 
the same extent as CEL-WT. After 72 h of transfection, the secretion of these variants had decreased 
even more, with very faint bands for CEL-DEL1 and CEL-TRUNC. Interestingly, for the 72 h 
transfection, CEL-DEL8 exhibited a stronger band in the medium than CEL-WT. Except for CEL-
TRUNC, all variants appeared as only one band, which probably corresponds to the fully glycosylated 





Figure 5.6 Comparison of expression, distribution and secretion in cellular fractions of CEL-variants without tags at 48 
and 72 h post-transfection. HEK293 cells were transiently transfected with plasmids encoding different CEL variants CEL-
WT, CEL-DEL1, CEL-DEL4, CEL-DEL8, CEL-TRUNC, CEL-3R and CEL-INS9. Lysate-, pellet- and medium fractions were 
collected 48 and 72 h post-transfection, and analysed by SDS-PAGE and Western blotting using CEL specific antibody 





5.5. The effect of CEL on cell viability and apoptosis  
5.5.1. Cell viability 
We examined all CEL variants to investigate the effect of both the epitope tag and VNTR length on cell 
viability. The cell viability experiments were performed in transiently transfected HEK293 cells. The 
cell viability was analysed 48 h post transfection by detecting the luminescence produced when 
luciferase converts luciferin to oxyluciferin and light. This takes place in the presence of ATP, Mg2+ and 
molecular oxygen, thereby indirectly measuring the ATP levels in the cells, which indicate metabolically 
active cells.  
The results are shown in Figure 5.7. Surprisingly, cells transfected with untagged CEL variants showed 
a higher overall cell viability compared to CEL-WT, except for CEL-TRUNC and EV. The experiment 
also indicated that some variants resulted in a higher viability than both untransfected control cells and 
CEL-WT, observed for both tagged and untagged. 
Interestingly, untagged CEL-DEL1 displayed a stronger impact on viability compared to CEL-WT, but 
this was not observed for the V5/His tagged variant. Variants that resulted in significant increased or 
reduced viability of HEK293 cells were: CEL-WT-V5/His, CEL-DEL1-V5/His, CEL-HYB-V5/His and 





Figure 5.7 The effect of CEL variants of HEK293 cell viability. Cell viability was measured as intracellular ATP levels. 
Results are presented as fold change of relative light units (RLU) for all variants compared to untransfected cells. The data 
shown are the mean of three experiments with ten technical replicates. ±SEM and p-values of statistical significance; *p≤0.05, 
**p≤0.01, ***p≤0.001. Red bars represent the V5/His tagged variants, while blue bars represent untagged variants. For variants 





We investigated the effect of all CEL variants on apoptosis in HEK293 cells. The cells were transiently 
transfected and analysed 48 h post transfection using the CellEvent Caspase-3/7 Green Detection Agent 
that detects Caspase 3/7 activity, a marker for apoptosis. Apoptosis was observed by confocal imaging 
as green cells or green nuclear fragments (Fig. 5.8 A, B and C). The number of apoptotic cells were 
quantified for each CEL variant and means of two independent experiments are presented in Figure 5.8 
D. 
Compared to CEL-WT-V5/His, showing 5.3 % apoptotic cells, there were an increase in apoptosis in 
HEK293 cells transfected with CEL-DEL1-V5/His, CEL-HYB-V5/His and CEL-TRUNC-V5/His, with 
total percentage of apoptotic cells being 10.7 %, 6.6 % and 7.7 %, respectively (Fig. 5.8 A, D). Cells 
transfected with empty vector showed 4.3 % of apoptosis, indicating that the transfection in itself was 
harmful to the cells. 
For the untagged CEL proteins, all variants except CEL-DEL8 had higher numbers of apoptotic cells 
than CEL-WT. CEL-DEL1, CEL-DEL4 and CEL-HYB showed considerably higher levels of apoptosis 
compared to CEL-WT, with 9.2 %, 8.2 % and 11.7 % against 4.3 %, respectively (Fig. 5.8 B, D).  
Slightly lower level of apoptosis was observed for CEL-TRUNC, CEL-3R and CEL-INS9, with 5.3 %, 













Figure 5.8 The effect of CEL variants on apoptosis. HEK293 cells were transiently transfected with plasmids encoding the 
different CEL variants. Apoptotic cells were detected using the apoptosis marker Caspase-3/7 Green Detection Agent. Confocal 
images of representative cells are shown in A, B, and C, and apoptotic cells are seen in green. A) Cells transfected with CEL-
WT, CEL-DEL1, CEL-HYB, CEL-TRUNC and EV containing the V5/His tag. B) Cells transfected with untagged CEL-WT, 
CEL-DEL1, CEL-DEL4, CEL-DEL8 and EV. C) Cells transfected with untagged CEL-WT, CEL-HYB, CEL-TRUNC, CEL-
INS9, CEL-3R and EV. D) The results presented are percentage of apoptotic cells of total number of cells (mean of two 
independent experiments ±SEM). P-values of significance was not performed as results were only available from two 
experiments. 
 
5.6. De-glycosylation of the CEL DEL1, -DEL4 and -DEL8 proteins 
Even though the three CEL deletion variants CEL-DEL1, -DEL4 and -DEL8 have different VNTRs, the 
expressed proteins are predicted to have the same molecular weight (around 73 kDa). This is illustrated 
in Figure 1.5 in the Introduction. However, when we analysed the expression of these three protein 
variants by Western blotting we observed bands with different molecular weight (see Fig. 5.6). Given 
that the CEL VNTR is heavily O-glycosylated, we wanted to examine if the difference in size could be 
due to such post-translational modification.  
To investigate the glycosylation patterns of the three deletion variants, medium from HEK293 cells 
transfected with CEL-DEL1, CEL-DEL4 or CEL-DEL8 were subjected to acetone precipitation and 
denaturation, before being treated with O- and N-glycosidases. Medium from cells transfected with 
CEL-WT was used as a positive control. The samples were analysed by SDS-PAGE and Western 
blotting and the result is presented in Figure 5.9.  
55 
 
The experiment revealed that exposure to N-glycosidase resulted in a small shift, while combined 
treatment with N- and O-glycosidase resulted in a relatively larger shift for all variants (Fig. 5.9). 
Interestingly, the three deletion variants did not display the same molecular size after both N- and O-
deglycosylation. When treated with both N- and O-glycosidase, CEL-DEL4 and DEL8 showed proteins 
of higher molecular weight than the CEL-DEL1 variant. 
 
 
Figure 5.9 De-glycosylation of CEL variants. Acetone precipitated proteins from medium of transiently transfected HEK293 
cells, expressing untagged CEL-WT CEL-DEL1, CEL-DEL4 and CEL-DEL8 were subjected to N-glycosidase (-N), to N- and 
O-glycosidase (-N/O) or no glycosidase treatment (-C). The samples were analysed with SDS-PAGE and Western blot. The 
proteins were detected with a CEL specific antibody (Pittsburgh). This experiment was performed once.  
 
To examine the glycosylation pattern in more detail, we used the NetOGlyc 3.1 server to estimate the 
numbers of theoretical glycosylation sites of each of the variants in Figure 5.9. The VNTR of CEL-WT 
was predicted to have a total of 36 O-glycosylation sites, while CEL-DEL1, -DEL4, and –DEL8 showed 
13, 18 and 22 sites, respectively (Figure 5.10). As well as the C-terminal O-glycosylation sites, all 
variants have an O-glycosylation of threonine at position 62 and a N-glycosylation of asparagine at 
position 210 in the globular domain. Taken together, these results indicate that the number of theoretical 





Figure 5.10 Theoretical N- and O-glycosylation sited predicted by the NetOGlyc3.1 server. The putative O- glycosylation 
sites for CEL-WT, CEL-DEL1, CEL-DEL4 and CEL-DEL8 were predicted to be a total 36, 13, 18 and 22, respectively. Also 
predicted was one N-glycosylation site positioned in the globular domain, position 210. O-glycosylation (red) and N-
glycosylation (blue) are illustrated for N-terminal globular domain in the upper panel and for the VNTR of CEL-WT and 
deletion variants in the lower panel.  
 
5.7. Isoelectric focusing 
Due to the deletion mutation, CEL-DEL1 has a different charge than the normal protein. CEL-WT 
consists of 22 negatively charged amino acids (17 Asp and 5 Glu), while CEL-DEL1 has 19 positively 
charged amino acids (19 Arg), which results in a higher theoretical isoelectric point (pI) (Johansson et 
al., 2011). The theoretical pI for CEL-WT protein is predicted to be 5.1, while CEL-DEL1 has a pI of 
9.5, not taking post-translational modifications or the epitope tag into account (ExPASy pI calculator). 
When analysing only the VNTR, CEL-WT has a pI of 3.3, while CEL-DEL1 has a pI of 11.8 
We wanted to further investigate the charge and isoelectric point of CEL variants due to differences in 
VNTR length and composition. Isoelectric focusing was performed on medium secreted from cells 
expressing CEL-WT or CEL-DEL1 with and without V5/His tag. The results were analysed by Western 
blot using both the anti-CEL (Pittsburgh) and anti-V5 antibodies.  
Although several of the bands appear as smears, CEL-WT and CEL-WT-V5/His have clear bands at 
approximately pH 6 (Fig. 5.11), which is in concordance with what was found using the pI predictor (pI 
5.1). We also observed that the V5/His tag only showed a minor shift in the pI of CEL-WT, suggesting 
that the effect of the V5/His tag on the isoelectric point of CEL is minor. 
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CEL-DEL1 exhibited no distinct bands, even when overexposing the blot. Instead, we observed a weak 
smear in the blot, located mainly in the alkaline part of the pH gradient, which is also in concordance 
with what was found using the pI predictor ExPASy. The same result has been observed by others in 
our group (El Jellas. pers. comm). For CEL-DEL1-V5/His, there was a distinct smear ranging from pH 
8.5 to pH 10 (Fig. 5.11), which could be due to differences in glycosylation patterns of the protein, 
leading to differently charged molecules of the same variant. 
 
  
Figure 5.11 Isoelectric focusing of V5/His tagged and untagged CEL-WT and CEL-DEL1. Medium samples from 
HEK293 cells expressing the variant were subjected to isoelectric focusing by separation on a pH gradient, and analysed by 





The digestive enzyme carboxyl ester lipase has been studied for decades (Hernell and Olivecrona, 1974, 
Lombardo et al., 1980b, Lombardo, 2001, Hui and Howles, 2002). Two of the CEL variants used in this 
project, CEL-DEL1 and CEL-HYB have been analysed extensively and are known to be associated with 
monogenic diabetes and chronic pancreatitis, respectively (Raeder et al., 2006, Johansson et al., 2011, 
Tjora et al., 2013, Fjeld et al., 2015, Xiao et al., 2016). When the CEL-DEL1 variant was published in 
2006, Ræder et al. also reported another disease-causing deletion variant, namely CEL-DEL4. 
Compared to CEL-DEL1, this mutation showed a seemingly milder phenotype of endocrine and 
exocrine dysfunction. Other CEL-variants normally occurring in the population were also observed, all 
showing varying lengths of the VNTR-region in CEL exon 11 (Raeder et al., 2006).  
In the present study, we have investigated whether a V5/His tag could influence the functional properties 
of CEL proteins expressed in cellular models. Moreover, we have examined the effect of different CEL-
VNTR lengths with regard to protein expression, secretion, modification and cell viability, to learn more 
about the role of the protein C-terminal in endocrine and exocrine pancreatic disease. Our main findings 
are discussed here. A complete overview of the variants used in this study is attached in Appendix I: 
CEL variants exon 11 DNA sequence and II: CEL variants exon 11 amino acid sequence. 
 
6.1. Comparison of V5/His tagged- versus untagged CEL protein variants 
In our previous studies analysing the disease mechanism of CEL-DEL1 and CEL-HYB in cellular 
systems, most results were based on the pcDNA3.1/V5-His vector from Invitrogen for protein 
expression (Johansson et al., 2011, Torsvik et al., 2014, Fjeld et al., 2015). This V5/His tag consists of 
a 14 amino acid V5 segment followed by a positively charged poly-histidine (6xHis) tag, which is fused 
to the C-terminal of the CEL protein. 
In this study, we compared the effect of the V5/His tag on CEL expression, secretion and localisation in 
HEK293 cells by Western blotting and immunostaining. The Western blots clearly showed stronger 
bands in the lysate- and pellet fractions for untagged CEL-WT, CEL-DEL1 and CEL-TRUNC (Fig. 5.3) 
as compared to the tagged variants. The exception was CEL-HYB, which showed more equal expression 
in the same fractions (Fig. 5.4). These results were confirmed by immunostaining: stronger signals were 
detected in cells transfected with CEL plasmids without V5/His, except for CEL-HYB. Thus, our 
findings indicate that the cellular properties of the CEL proteins are influenced by the epitope tag, and 
that the epitope tag may indeed render CEL variants more soluble. 
One study has been performed on CEL-DEL1 without V5/His tag (Xiao et al., 2016). Here, the authors 
observed intracellular aggregates and activation of the unfolded protein response (UPR) in transfected 
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cells, similar to our previous findings with the tag (Johansson et al., 2011, Xiao et al., 2016). However, 
they also observed impaired protein secretion and induced apoptosis, suggesting an even stronger 
pathogenic effect without the V5/His tag.  
It is also interesting to see that CEL-HYB and CEL-TRUNC, the two variants with the shortest VNTR 
domains, were detected as the most abundant in the pellet fraction (Fig. 5.3, 5.4). In addition, these 
variants showed dramatically impaired secretion compared to CEL-WT, suggesting that the size 
and/or the composition of the C-terminal domains has an effect on the secretion of CEL. As for CEL-
HYB, this is in line our previous report showing intracellular retention and impaired secretion of this 
protein (Fjeld et al., 2015). However, the fact that CEL-HYB V5/His, but not CEL-HYB was detected 
in the medium (Fig. 5.4), further confirms that the V5/His tag has an effect on the functional properties 
of CEL. 
 
6.2. The effect of CEL VNTR lengths on protein expression, localisation and secretion  
Next, we investigated the effect of CEL VNTR lengths (without V5/His tag) on protein expression, 
secretion and localisation in HEK293 cells. By cell fractionation and Western blot analysis, we found 
the same trend after both 48h and 72h transfection (Fig 5.6). Most interestingly, CEL-DEL1 and CEL-
DEL4 were less secreted compared CEL-WT. Thus, for the first time we show reduced secretion for 
both CEL-MODY variants. Furthermore, we observe that variants found in the normal population are 
secreted similarly to the normal protein (CEL-DEL8, CEL-3R and CEL-INS9). 
Another interesting finding is that the three deletion variants (DEL1, DEL4 and DEL8) migrate with 
different sizes in all cell fractions (Fig. 5.6). As these variants have the same theoretical size, but are 
likely to differ in VNTR glycosylation patterns (Fig. 5.10), suggests that the shift in band size is due to 
different post-modification. This is further discussed in section 6.4.   
We also observe higher molecular bands for several of the CEL variants in both lysate and pellet 
fractions (Fig. 5.3, 5.4 and 5.6). We know that CEL-WT, CEL-DEL1 and CEL-HYB are cleared from 
transfected HEK293 cells by proteosomal degradation (Johansson et al., 2011, Torsvik et al., 2014) 
(Fjeld. pers. comm.), indicating that the higher molecular forms could be ubiquitinated proteins targeted 
for degradation. We also speculate that there could be oligomeric/dimeric forms of CEL but this needs 
to be further investigated.   
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6.3. The effect of CEL variants on cell viability and apoptosis in HEK293 cells 
Given the pathogenic nature of CEL-DEL1, -DEL4 and -HYB, it was surprising to see that all three 
variants, both untagged and V5/His tagged, led to an increase in cell viability compared to CEL-WT 
(Fig. 5.7). Actually, of all the variants, only cells transfected with CEL-TRUNC or EV showed a reduced 
viability compared to the normal CEL protein.  
Previous reports have found that CEL-DEL1 has a negative impact on cell viability (Johansson et al., 
2011, Xiao et al., 2016). The most recent article showed that CEL-DEL1 increases cell death in 
transiently transfected HEK293T cells, however, the effect was most prominent after 72h and 92h 
transfection (Xiao et al., 2016). It has also been shown that cells may have an increase in ATP before 
undergoing apoptosis, perhaps due to activating all survival mechanisms (Zamaraeva et al., 2005). Thus, 
given that our cell viability assay relies on measuring ATP and that we analysed our cells 48 h post 
transfection, we speculate that our results could have been different if the measurement had been 
performed at a later time point. 
Compared to the cell viability results, we observe a different trend when analysing our transfected cells 
for apoptosis. Now, elevated levels of apoptosis were observed for cells transfected with disease-causing 
variants (Fig. 5.8). This is in line with a previous report (Xiao et al., 2016) and suggests that programmed 
cell death is a result of the altered physicochemical properties of the pathogenic variants. It was 
interesting to observe that cells transfected with CEL-DEL8, CEL-INS9 and CEL-3R all displayed lower 
or similar levels of apoptosis compared to CEL-WT, indicating no toxic effect of CEL variants detected 
in the healthy population. 
In addition, for the apoptosis assay, most variants with tag led to a higher percentage of apoptotic cells 
compared to the untagged variants. This leaves the question of whether the tag could be harmful in any 
way. One explanation could be that a higher secretion rate of the tagged variants could lead to higher 
levels of endocytosis, followed by induced apoptosis. The exception was CEL-HYB, which showed a 
higher percentage of apoptotic cells for the untagged variant. Perhaps this is caused by the strong 
tendency of CEL-HYB to be retained inside the cell (Fjeld et al., 2015), and that the untagged variant is 
more toxic to the cells. To support this hypothesis, the untagged CEL-HYB also showed reduced cell 
viability (Fig. 5.7) and reduced secretion (Fig. 5.4) compared to the tagged variant. 
Another important observation in this study is that transient transfection in itself can be harmful to cells 
(Juckem, 2012), indicated by the low viability and a relative high level of apoptosis in cells transfected 
with EV (Fig. 5.7, 5.8).  
The fact that results on viability and apoptosis show opposite trends are difficult to explain. Long term 
exposure of CEL variants could be resembling the late onset disease of CEL-MODY and CEL-HYB 
more. However, viability assays performed by our group on cells stably expressing pathogenic CEL 
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variants did not show reduced cell viability. It would be interesting to perform a virus-mediated 
transfection, which would increase the time period of expression, thus allowing us to study the effect of 
the variants for a longer time (Durocher et al., 2002). The advantages of using virus-mediated 
transfection are plentiful; it is highly efficient, easy to use, and results in sustainable transgene 
expression after integration in the host genome (Hacein-Bey-Abina et al., 2002, Roesler et al., 2002). 
However, one must keep in mind that viral transfection can result in cytotoxicity (Woods et al., 2003, 
Kim and Eberwine, 2010).  
 
6.4. CEL VNTR sequence and length alter glycosylation and protein charge  
6.4.1. De-glycosylation of CEL-DEL1, -DEL4 and -DEL8  
Glycosylation is a very complex post-translational modification characterized by the addition of a 
monosaccharide, or an oligosaccharide chain in a specific manner to macromolecules such as proteins. 
Two predominantly classes of glycosylation exist; N- and O-glycosylation (Nelson and Cox, 2008, 
Varki, 2009). N-glycosylation occurs co-translationally in the ER at the consensus sequence N-X-T/S 
(where N is an asparagine residue, X is any residue except proline, and T/S are serine or threonine 
residues). O-glycosylation however, occurs post-translationally in the Golgi apparatus on serine or 
threonine residues. During this complex process, different glycosidases participates in assembling 
glycosylation structures on the protein (Varki, 2009). The different residues can be assembled in 
different configurations, with different types of glycosidic bonds, which subsequently provides a high 
amount of different structural moieties that can affect the biochemical properties of a protein (Nelson 
and Cox, 2008, Varki, 2009). 
As mentioned before in this discussion (section 6.2), we found it very interesting that these three CEL 
deletion variants migrated with different sizes (Fig. 5.6), given that they all have an estimated weight of 
73 kDa (Fig 1.5). However, when looking more closely into the theoretical glycosylation pattern of 
CEL-DEL1, -DEL4 and -DEL8, we found them to differ greatly. The number of theoretical O-
glycosylation sites actually decreased with the length of the altered VNTR (Fig. 5.10). Thus, the more 
proximal the deletion appeared in the VNTR, the more glycosylation sites were lost in the resulting 
protein. The differences in the number of O-glycosylation sites, are however only predicted, since it is 
not yet known how many of these theoretical sites are actually occupied by glycans, or what their actual 
structure is. 
To look more into this, we treated the different variants with N- and O-glycosidases. The results showed 
that CEL-DEL1, -DEL4 and -DEL8 did not result in the same molecular size after treatment with both 
N- and O-glycosidases (Fig. 5.9).  
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Based on the shifts we observed, one could speculate the more glycans the variants consist of, the fewer 
glycans have actually been removed. This could be due to limited access for the glycosidases when the 
protein is heavily modified. To support this, we observe that CEL-WT, being the most O-glycosylated 
form of the CEL variants with 37 sites, has a shift more similar to CEL-DEL8 (22 sites) than CEL-DEL1 
(13 sites). 
Given that O-glycosylation of the CEL-VNTR is thought to be important for both stability and secretion 
of the protein (Rogers et al., 1986, Bruneau and Lombardo, 1995, Bruneau et al., 1997), it is interesting 
to observe that CEL-DEL1, CEL-DEL4 and CEL-HYB, which all are low in the numbers of 
glycosylation sites (13, 18 and 3, respectively) are variants found less secreted (Fig. 5.4 and Fig. 5.6).  
However, both N- and O-glycosylation are complex modifications, varying depending on the cell/tissue 
from which it is secreted (Landberg et al., 1997). Furthermore, CEL has O-glycans with an average of 
7-8 sugars per O-glycan molecule, each with a high degree of structural diversity (Wang et al., 1995, 
Landberg et al., 1997, Landberg et al., 2000). Also, one study found that CEL in mother’s milk had 
dramatically different compositions and levels of sialyated O-glycan and fucosylated N-glycan 
structures in different stages of lactation, and suggested that glycosylation of CEL depends on several 
factors including blood group phenotype and hormonal regulation of glycosylic transferases (Landberg 
et al., 2000). Thus, the role of CEL glycosylation in pancreatic disease is complex and further studies 
are needed to analyse this in more depth. 
 
6.4.2. Isoelectric focusing 
As mentioned above, the frame shift mutation in CEL-DEL1 leads to more positively charged amino 
acids, and an additionally predicted increase in pI from 5.2 to 9.5 compared to the normal protein. To 
investigate if the theoretical predictions of charge of CEL-WT and CEL-DEL1 are correct, we 
performed isoelectric focusing on these variants. Glycans may also play an important role in altering the 
charge, as both N- and O-glycosylation often contain the negatively charged sialic acid sugar residues 
(Eylar et al., 1962). The abundance of O-glycosylation of the VNTR should in theory render the C-
terminal hydrophilic and charged (Wang et al., 1995).  
Although no information could be obtained from untagged CEL-DEL1, CEL-DEL1-V5/His had a strong 
band located in the blot, albeit quite smeared, as did the other samples. These smeared bands observed 
reflect the complexity of working with glycosylated proteins. The glycans are often heterogeneous, 
which would result in differently glycosylated CEL molecules, due to micro-heterogeneity (Fig. 5.11). 
The glycans do not necessarily have the same conformation in each CEL molecule, and each CEL 
molecule may have a different pattern of glycans, which would give the protein molecules different pI 
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values, and thus present at different points along the pH gradient (Landberg et al., 1997, McKillop et 
al., 2004). 
CEL-DEL1-V5/His is located mainly in the alkaline part of the pH gradient, in concordance with the pI 
predictor, and with results from a two dimensional gel (El Jellas. pers. comm). The smear may 
correspond to fully glycosylated proteins at the upper part, and partly glycosylated proteins at the lower 
part. If the CEL-DEL1 variant is less glycosylated, a possible explanation could be related to the high 
number of cysteine residues. It has been reported that the excess of cysteines residues that appear in the 
new C-terminal could lead to aggregation of the protein via formation of disulphide bridges, and 
subsequently large protein aggregates (Xiao et al., 2016). If this is the case, this may compromise the 
ability and access of glycosidases to the sites that could be exploited for glycosylation (i.e. a serine or a 
threonine), leading to even fewer O-glycans for CEL-DEL1. In any case, we cannot exclude the 
possibility of other post-translational modifications could occur simultaneously in different variants 
such as protein phosphorylation, or acetylation, and none, except glycosylation have been examined in 
this work. 
For both CEL-WT and CEL-WT His/V5, the bands at approximately pH 6-8 are likely partly- and fully-
glycosylated forms, as that will render the protein more acidic. The smear at pH ~ 5 may be non-
glycosylated forms, correlating to the predicted pI values for CEL-WT (NetOGlyc3.1), with a slight 
shift from tagged to untagged variant. However, as the bands at approximately pH 4 can also be seen 
for both variants of CEL-DEL1, although weakly, one could speculate if these are non-glycosylated 
forms of the globular domain of the CEL variants, 
Detecting the variants with the anti-V5 antibody serves as a control as it only detects the C-terminal of 
the variants (Johansson et al., 2011). CEL-WT-V5/His occurs in the acidic part of the pH gradient at pH 
3-5 corresponding to the predicted pI value of the VNTR at 3.3, while CEL-DEL1-V5/His has a strong 
band in the more alkaline part at pH 9-10 (Fig. 5.11). The smears could be O-glycosylated forms with 
fewer/other glycans, as the pI corresponds to the pI of the two variants VNTR domains (Johansson et 
al., 2011).  
It would be interesting to include the other CEL variants, especially the deletion variants, and also 
variants devoid of N-glycans, to conclude if the upper alkaline smear is the N-glycan. For further 




6.5. HEK293 cells as a research tool for studying CEL 
The HEK293 cells are a specific cell line that originally derived from Human Embryonic Kidney cells 
and they are a well-known tool in cell biology research. The reasons behind this is that they are easy to 
culture, easy to transfect, and they proliferate rapidly. For our studies, it is also an advantage that they 
are secretory cells and that they do not express the CEL protein endogenously. Additionally, the cells 
are of human origin, which is essential when studying post-translational modifications of our CEL 
variants. 
However, there are limitations when choosing the HEK293 cell line for CEL-related projects as these 
cells do not give a representative physiological presentation of how the CEL variants would behave in 
pancreatic cells. For example, even though they are secretory cells, the HEK293 cells do not have the 
characteristic zymogen granules of the acinar cells. The best option would be to use primary acinar cells, 
but they are hard to get hold of, difficult to obtain in long-term culture models, sensitive to work with, 
and often loses their secretory differentiation (Blinman et al., 2000, Lardon and Bouwens, 2005). There 
are two commercially available acinar cell lines, one deriving from mouse (266-6 cells) and one from 
rat (AR42J). Our research group have used the 266-6 cells for endocytosis experiments (Torsvik et al., 
2014), however we have had no success with liposomal transfection or electroporation of the cells. Thus, 
we need to start using virus transfection, a method that has shown to be very successful for studying 




7. Conclusions  
The pathogenic variants of CEL are associated with diabetes (CEL-DEL1 and CEL-DEL4) and 
pancreatitis (CEL-HYB). Here, the overall objective was to understand more of the role of the CEL 
protein C-terminal in pancreatic disease. 
The findings in this study suggest that the properties of the CEL protein variants expressed in HEK293 
cells are influenced by the presence of an epitope tag, which leads to an underestimation of their 
propensity to accumulate and aggregate. This could be relevant for the interpretation of previous results 
from our group regarding the pathogenic variants CEL-DEL1 and CEL-HYB. In addition, we observed 
that CEL protein variants are influenced by the VNTR lengths and composition, and that O-
glycosylation possibly has an important impact on CEL variant expression, secretion and cellular fate. 
The disease-causing protein variants CEL-DEL1, CEL-DEL4 and CEL-HYB resulted in elevated 
intracellular accumulation and increased apoptosis compared to the CEL-WT. Finally, we found 
evidence that of the three deletion variants, the first VNTR repeat contains more accessible O-




8. Future perspectives 
We have the following plan for further investigations: 
 The experiments performed in this study will have to be repeated three times with similar results 
before publication. 
 The CEL mutation carriers are heterozygous. It would therefore be interesting to study all 
variants investigated here when co-expressed with CEL-WT, to see the effect of the disease 
related variant on the normal protein.  
 It would be beneficial to perform the experiments with stably transfected cells to obtain long 
time expression. This would better fit the disease mechanism of late onset disease. 
 Further studies on the glycosylation patterns and pI of the different CEL variants to understand 
more of the role of glycans and charge in molecular interactions and disease mechanism.  
 Characterization of the glycosylation-profiles of CEL-variants in duodenal juice from affected 
patients or healthy individuals with varying VNTR-lengths. 
 It would be beneficial and more realistic in terms of physiology to investigate the CEL variants 
in a pancreatic acinar cell line, or in animal models. Transgenic mouse expressing human CEL-
WT, CEL-DEL1 and CEL-HYB are now being made by our group. 
 In addition, measuring the enzymatic activity of each variant would be interesting, as such 
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I: CEL variants exon 11 DNA sequence 
 
Green:    V5-tag 
Purple:    Poly-histidine tag    
Blue:    XhoI seat 





(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(4) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(5) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(6) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(7) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(8) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(9) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(10) GGC GCC CCC CCC GTG CCG CCC ACG GGT GAC GCC 
(11) GGG CCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(12) GGC GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(13) GGG GCC CCC CCC GTG ACC CCC ACG GGT GAC TCC 
(14) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(15) GGG GCC CCC CCT GTG CCC CCC ACG GGT GAC TCT 
(16) GAG GCT GCC CCT GTG CCC CCC ACA GAT GAC TCC 
                                                 XhoI     
AAGGAAGCTCAGATGCCTGCAGTCATTAGGTTTTCCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTA 






(1) GAG GCC ACC CCG TGC CCC CCA CAG GGG ACT CC 
(2) G AGG CCA CTC CCG TGC CCC CCA CGG GTG ACT CC 
(3) G AGA CCG CCC CCG TGC CGC CCA CGG GTG ACT CC 
(4) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(5) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(6) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(7) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(8) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(9) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(10) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACG CC 
(11) G GGC CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(12) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(13) G GGG CCC CCC CCG  
                                                XhoI     
AAGGAAGCTCAGATGCCTGCAGTCATTAGGTTTTCCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTA 






(1) CGA CCA GGA GGC CAG TTC CAT GCC CTC CAC AGG 
(2) GGA CTC TGA GGC CAC TCC CGT CTC CCC CGA CAG 
(3) GCA ACT CCG AGT CTG CCC CCG TCC CTG CAA CGG 
                                       XhoI     
AAGGAAGCTCAGATGCCTGCAGTCATTAGGTTTTCCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTA 







(1) GAG GCC ACC CCT 
                                                XhoI     
AAGGAAGCTCAGATGCCTGCAGTCATTAGGTTTTCCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTA 






(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(4) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(5) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(6) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(7) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(8) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(9) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(10) GGC GCC CCC CCC GTG CCG CCC ACG GGT GAC GCC 
(11) GGG CCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(12) GGC GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(13) GGG GCC CCC CCC GTG ACC CCC ACG GGT GAC TCC 
(14) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(15) GGG GCC CCC CCT GTG CCC CCC ACG GGT GAC TCT 
(16) GAG GCT GCC CCT GTG CCC CCC ACA GAT GAC TCC 
                 STOP 





(1) GAG GCC ACC CCG TGC CCC CCA CAG GGG ACT CC 
(2) G AGG CCA CTC CCG TGC CCC CCA CGG GTG ACT CC 
(3) G AGA CCG CCC CCG TGC CGC CCA CGG GTG ACT CC 
(4) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(5) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(6) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(7) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(8) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(9) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(10) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACG CC 
(11) G GGC CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(12) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(13) G GGG CCC CCC CCG   
                 STOP 





(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(4) GGG GCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(5) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(6) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(7) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(8) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(9) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(10) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACG CC 
(11) G GGC CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(12) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(13) G GGG CCC CCC CCG  
                         STOP 






(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(4) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(5) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(6) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(7) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(8) GGG GCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(9) G GGG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(10) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACG CC 
(11) G GGC CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(12) G GCG CCC CCC CCG TGC CGC CCA CGG GTG ACT CC 
(13) G GGG CCC CCC CCG  
                        STOP 





(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
(4) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(5) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(6) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(7) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(8) GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 
(9) GGG GCC CCC CCC GTT GCC GCC CAC GGG  
                 STOP 





(1) GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC 
(2) GAG GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC 
(3) GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC 
                 STOP 





(1) CGA CCA GGA GGC CAG TTC CAT GCC CTC CAC AGG 
(2) GGA CTC TGA GGC CAC TCC CGT CTC CCC CGA CAG 
(3) GCA ACT CCG AGT CTG CCC CCG TCC CTG CAA CGG 
                  STOP 





(1) GAG GCC ACC CCG  
                        STOP 




II: CEL variants exon 11 amino acid sequence 
 
Yellow:    Signalling peptide 
Blue:    VNTR region 
Purple:    V5-tag 
Green:    Poly-histidine tag 
T:    Threonine position 62 – O-glycosylation 
N:    Asparagine position 210 – N -glycosylation 

























































































































































      
 
 
